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RESUMO 
O Sistema Nervoso Central caracteriza-se por uma organização estrutural em sinapses 
multipartidas, constituídas por diversos tipos celulares que coexistem em contínua inter-relação, 
estabelecendo a base funcional da homeostasia. 
A Adenosina, ao ser um metabolito presente em todos os subtipos celulares, ganha relevância 
pela sua capacidade de modular a função cerebral através de acções a nível da transmissão 
sináptica – regulando a libertação de neurotransmissores, excitabilidade pós-sináptica e resposta 
de vários tipos de receptores – e da fisiologia das células gliais. Esta modulação homeostática é 
mediada pela acção de quatro receptores pleiotrópicos (A1, A2A, A2B and A3) que activam diferentes 
vias de transdução, de acordo com o seu grau de activação e localização celular e subcelular. 
Particularmente a nível do hipocampo, a acção deste importante neuromodulador resulta de um 
balanço entre as respostas inibitórias dos receptores A1 e os efeitos facilitadores da activação dos 
receptores A2A. 
Os receptores A2A são receptores metabotrópicos excitatórios que, apesar de pouco expressos a 
nível do hipocampo, actuam como metamoduladores da actividade sináptica, através da regulação 
da libertação de glutamato, GABA e acetilcolina, aliada à interacção com diversos receptores de 
neuromoduladores, neurotransmissores e neurotrofinas. Além do controlo da função neuronal, as 
suas acções estendem-se à função dos astrócitos e da microglia, ocupando uma posição de 
destaque na modulação das relações funcionais entre diversos tipos celulares. 
Diversos estudos relacionam situações de insulto - tais como stress, epilepsia, hipoxia, isquémia 
e envelhecimento – caracterizadas por um aumento extracelular da concentração de adenosina, 
com a indução de uma desregulação do sistema adenosinérgico, devido à sobreexpressão de 
receptores A2A a nível do córtex e hipocampo, levando a fenómenos de excitotoxicidade, retracção 
dendrítica e alterações da memória e plasticidade sináptica. Embora o mecanismo subjacente a 
esta sobreexpressão patológica permaneça desconhecido, bem como o subtipo neuronal 
directamente afectado, sabe-se que este tipo de situações prejudiciais à fisiologia do sistema 
nervoso induzem alterações que seguem a mesma tendência daquelas que ocorrem com o 
envelhecimento. 
De forma a permitir o estudo da desregulação destes receptores no hipocampo, foi criado um 
modelo de ratos transgénicos que sobreexpressa o subtipo humano do receptor A2A sob o controlo 
do promotor da proteína cinase dependente de cálcio/calmodulina (Tg(CaMKII-hA2AR)), permitindo 
uma sobreexpressão pós-natal a nível dos neurónios do prosencéfalo, que mimetiza o processo 
patológico decorrente de circunstâncias de insulto. Sabendo que estes animais apresentam 
alterações semelhantes às do envelhecimento, com consequências a nível cognitivo, sináptico e 
molecular, o presente estudo teve como objectivo avaliar a contribuição de diversos subtipos 
celulares para este comprometimento da função do hipocampo. 
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Em primeiro lugar, de forma a abordar as consequências desta sobrexpressão a nível dos circuitos 
neuronais do hipocampo, foram efectuadas diversas técnicas de biologia molecular para 
caracterizar a sua localização neste modelo transgénico, tendo sido confirmado através de 
imunohistoquímica que estes animais expressam o receptor A2A humano nas projecções axonais 
de CA3 e a nível de CA1 e do Girus Dentado. 
Após esta caracterização, avaliou-se se as alterações induzidas no hipocampo estariam 
relacionadas com perda neuronal ou modificações na densidade sináptica. Não foram encontradas 
diferenças significativas no número de neurónios da camada piramidal de CA1 nem nos níveis 
proteicos de marcadores de densidade sináptica (PSD-95 e SNAP-25)  no hipocampo de animais 
Tg(CaMKII-hA2AR) e WT. 
A segunda parte do estudo consistiu na avaliação de possíveis alterações a nível do fenótipo das 
células da microglia e dos astrócitos, explorando a sua contribuição para o processo patológico. 
Procedeu-se à caracterização do fenótipo das células da microglia, através de uma abordagem 
combinada de Western Blotting, imunohistoquímica e citometria de fluxo. Paralelamente a um 
aumento significativo de 66.91 ± 24.77% dos níveis proteicos de Iba1 no hipocampo de animais 
transgénicos, foram encontradas diferenças morfológicas significativas relativas à diminuição da 
área de influência celular (4,64x108 ± 5,134x107 µm2) e à aquisição de uma morfologia menos 
arredondada da microglia na região de CA1 de animais transgénicos, comparativamente aos WT. 
No entanto, não foram encontradas diferenças significativas em relação ao número de células 
microgliais e aos níveis de expressão de CD11b. 
Os resultados obtidos demonstram que a sobreexpressão neuronal de receptores A2A é suficiente 
para desencadear alterações ao nível do fenótipo da microglia, semelhantes às que caracterizam 
as fases iniciais do seu processo de activação. A existência de um estado crónico de activação da 
microglia pode levar ao estabelecimento de um ambiente pró-inflamatório, devido à libertação de 
citocinas e mediadores inflamatórios, com possível contribuição para as alterações verificadas ao 
nível da plasticidade sináptica do hipocampo neste modelo transgénico. 
Por fim, procedeu-se à caracterização do fenótipo dos astrócitos, através de Western Blotting e 
imunohistoquímica. Observou-se uma diminuição da reactividade dos astrócitos, pela diminuição 
significativa de 20.76 ± 8.019% dos níveis de GFAP no hipocampo de animais transgénicos 
comparativamente aos WT. No que diz respeito à análise morfológica destas células, não foram 
encontradas diferenças significativas na densidade, distribuição e morfologia dos astrócitos da 
região de CA1 entre animais transgénicos e WT. 
A sobreexpressão de receptores A2A a nível neuronal induz uma diminuição de reactividade dos 
astrócitos, consistente com um fenótipo de astenia. A perda de função dos astrócitos é uma 
característica importante do processo de neurodegeneração, com prejuízo da função neuronal 
resultante de um desajuste homeostático, nomeadamente ao nível da disfunção dos 
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transportadores de glutamato. Diminuições dos níveis de GFAP estão também correlacionadas com 
patologia depressiva em humanos e modelos animais, o que é consistente com as características 
depressivas presentes neste modelo de sobreexpressão de receptores A2A previamente analisadas 
através de estudos comportamentais. Assim, as alterações verificadas ao nível sináptico e 
comportamental nos animais transgénicos podem em parte ser explicadas por uma alteração da 
função dos astrócitos. 
O presente trabalho comprova que a sobreexpressão de receptores A2A em neurónios é suficiente 
para induzir alterações significativas ao nível da função das células gliais. Deste modo, as 
consequências cognitivas, sinápticas e moleculares que decorrem da desregulação dos receptores 
A2AR no hipocampo, em contextos de insulto para a fisiologia do sistema nervoso, derivam de uma 
desregulação conjunta de células neuronais e gliais, num mecanismo semelhante ao do 
envelhecimento. 
Para além de contribuir para melhorar o conhecimento sobre os processos neuropatológicos, este 
estudo reforça a necessidade de considerar a neurodegeneração como uma consequência da perda 
de homeostasia, dando igual relevância à contribuição das alterações funcionais, celulares e 
moleculares a nível neuronal e das células da glia. 
 
 
Palavras-chave: Adenosina; receptor A2A; neurodegeneração; microglia, astrócitos, hipocampo; 
sinapse 
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ABSTRACT 
Adenosine A2A receptors (A2AR) are excitatory metabotropic receptors that act as metamodulators 
of synaptic activity in the hippocampus, by influencing the release/uptake of glutamate, GABA and 
acetylcholine together with the interaction with receptors for other neuromodulators, 
neurotransmitters and neurotrophic factors and the modulation of glial cell function. 
Noxious brain conditions, such as stress and aging, are known to induce a dysregulation of 
adenosinergic system characterized by long-term robust upregulation of A2AR in cortical and 
hippocampal regions, leading to an imbalance of the overall effect of adenosine with excitotoxixity 
phenomena, dendritic retraction and memory and synaptic plasticity impairment. Although little is 
known on the mechanism involved in this A2AR upsurge, different studies have found common 
features between this type of dysregulation and those found in aged animals, raising an early-aging 
hypothesis behind neurodegeneration. 
In order to clarify the involvement of different cellular subsets in the A2AR hippocampal 
dysregulation, we characterized glial cell phenotype in a model of transgenic rats with a postnatal 
overexpression of human A2AR conditional to the glutamatergic forebrain neurons (Tg(CaMKII-
hA2AR)) that displays age-like alterations in hippocampal function, with cognitive, synaptic and 
molecular impairments. 
We found that human A2AR overexpression in forebrain neurons is sufficient to drive significant 
changes in glial cell function, inducing a primed state of microglia – triggering morphological 
alterations that resemble early states of activation process – and an asthenic phenotype of 
astrocytes by decreasing GFAP expression. Therefore, the pathological process of A2AR 
dysregulation derives from a synergy of synaptic and glial dysfunction that resembles features of 
hippocampal aging. 
By highlighting the importance of considering neurodegeneration as a consequence of homeostatic 
failure, results give relevance to the molecular and cellular changes in glia as well as neurons, when 
trying to decipher the mechanisms leading to neuropathology, suggesting A2AR as a promising 
multifactorial tool of therapeutic interest. 
 
 
Key Words: Adenosine A2A receptor; overexpression; neurodegeneration; microglia; astrocyte; 
hippocampus; multipartite synapse; microglial activation; astroglial asthenia. 
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1 | INTRODUCTION 
1.1 | Adenosine: coordinator of brain function 
Adenosine is a purine nucleoside produced through the catabolism of ATP by ecto-nucleotidases. 
Ubiquitously present in all cell types, its ability to modulate cell metabolism is widely described, 
namely in Central Nervous System (CNS), where it is considered a homeostatic coordinator of brain 
function, able to influence synaptic transmission, triggering or braking the activity of different 
neurotransmitters and neuromodulators (Ribeiro & Sebastião, 2010). Accordingly, adenosinergic 
system is responsible for the control of the flow of information rather than its transmission, regulating 
neurotransmitter release, post-synaptic excitability and the response of several brain receptors 
(Cunha, 2005; Sebastiao & Ribeiro, 2009). Moreover, this modulatory potential is also extended to 
astrocytes, microglia and oligodendrocytes, being well positioned to mediate neuron-glia 
communication (Daré et al., 2007). 
The neuromodulatory role of adenosine is mediated by four pleiotropic receptors -– A1, A2A, A2B 
and A3 – that couple to different G proteins, activating different transducing pathways according to 
their degree of activation and cellular and sub-cellular localization. Nonetheless, the impact of 
adenosine on brain function is mostly defined by a dynamic balance between the inhibitory and 
excitatory actions of A1 and A2A receptors, respectively. In fact, the differential activation of these 
receptors with opposing outcomes consists of a function of the activity of nerve terminals, with the 
effects of A1 receptors predominating at low frequencies of stimulation and a preferential activation 
of A2A receptors following high frequencies (Cunha, 2005). Although A1 and A2A receptors are 
widespread in the CNS, their relative proportions differ greatly according to the brain region. While 
A1 receptors are more abundant in the cortex, cerebellum and hippocampus, A2A display a more 
restricted expression pattern with high density in basal ganglia (Ribeiro et al., 2003). 
 
 
Figure 1.1 - Schematic representation of the distribution of adenosine receptors in the brain.  
The hippocampus presents high levels of A1R and low levels of A2AR (from Ribeiro et al., 2003) 
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1.2 | A2AR in hippocampal physiology and disease 
In spite of their low density in the hippocampus, with predominant presynaptic localization, A2A 
receptors (A2AR) play an important role in the modulation of synaptic transmission, not restricted to 
the control of neuronal function but also through their impact on astrocytic and microglial function. 
The metamodulator properties of A2AR reflect their ability to facilitate the release of most 
neurotransmitter types, along with their regulation of the function of metabotropic, ionotropic and 
catalytic receptors of other modulatory systems (Sebastiao & Ribeiro, 2009; Ribeiro & Sebastião, 
2010). Pre-synaptically, A2AR activation modulates the release or uptake of glutamate, acetylcholine 
and GABA (Cunha, 2005). In glutamatergic terminals, these receptors possess release-regulating 
properties, leading to facilitation of glutamate release and synaptic transmission, through different 
mechanisms, such as: (1) a cross-talk with A1 receptors (A1R)– decreasing their binding affinity and 
tonic inhibition, in a manner dependent on intracellular transduction (Lopes et al., 2002); (2) 
promoting K+-evoked glutamate release (Marcoli et al., 2003), and by (3) a synergistic interaction 
with mGlu5 receptors, enhancing their responses (Tebano et al., 2006). Moreover, their activation of 
Adenylate Cyclase/Protein Kinase A (AC/PKA) pathway has effects on cholinergic and GABAergic 
transmission, promoting acetylcholine release (Rebola et al., 2002) and enhanced GAT-1 mediated 
GABA transport into nerve endings (Cristóvão-Ferreira et al., 2009). Furthermore, at post-synaptic 
level, A2AR interact and modulate the activity of different types of receptors, namely enhancing AMPA 
receptors-evoked currents and facilitating NMDA receptor functioning (Ribeiro & Sebastião, 2010; 
Sebastiao & Ribeiro, 2009). Additionally, their activation is a crucial requisite for the functioning of 
neurotrophic receptors, being able to transactivate TrkB receptors in the absence of Brain Derived 
Neurotrophic Factor (BDNF) (Lee & Chao, 2001). On the other hand, as A2AR are pleiotropic 
receptors it is also important to highlight their ability to signal through PKA-independent pathways, 
including PKC (R. A. Cunha & Ribeiro, 2000), MAPK (Schulte & Fredholm, 2003), β-arrestin (Khoa 
et al., 2006) and Src-TrkA (Malek et al., 1999) as well as to bind to several interacting proteins, which 
can complement and modulate their G-protein-dependent function (Fredholm et al., 2007). 
These complex interactions may justify the apparent paradoxical effects of these receptors. In fact, 
while A2AR activation was reported to play a protective role in cases of intracerebral hemorrhage, 
hippocampal kainate-induced excitotoxicity, striatal lesion and spinal cord injury, strategies of 
genetic and pharmacological inactivation of the same receptor have been proven to afford 
neuroprotection in contexts of dopaminergic neurodegeneration, excitoxicity, β-amyloid aggregation 
and traumatic brain injury, as well as to reduce cognitive impairment and decrease Aβ levels in the 
brain of transgenic mouse models of Alzheimer’s Disease (AD) (reviewed in Dai et al., 2010). 
Noteworthy, extracellular adenosine and glutamate levels rise rapidly and dramatically in response 
to brain insults, due to increased ATP release and altered glutamate presynaptic neuronal release/ 
astrocytic reversal uptake, respectively. Higher levels of adenosine activate preferentially A2AR and 
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cause A1R desensitization, favouring glutamate release (Cunha, 2005). Thus, this interplay between 
adenosine and glutamate levels defines the functional outcome of A2AR, being responsible for a 
feedforward loop that leads to neurodegeneration. Therefore, this dual neuroprotective potential of 
A2AR modulation seems to be dependent on the specific profile of the pathology and the stage of the 
pathological where the exposure to agonists or antagonists occurs (Dai et al., 2010). 
In fact, although tonic inhibitory activity of A1R counteracts A2AR facilitatory effects at physiological 
state (Lopes et al., 2002), different noxious brain conditions - such as hypoxia, ischemia, epilepsy, 
stress or aging - in which there is a modification of the extracellular metabolism of adenosine, are 
related to a decrease in expression and density of A1R and a long term robust upregulation of A2AR 
in cortical and hippocampal regions. This imbalance of the overall effect of adenosine causes greater 
susceptibility of brain tissue to stressful stimuli and neuronal damage, leading to excitotoxicity, 
dendritic retraction and memory and synaptic plasticity impairment (Cunha, 2005; Batalha et al., 
2013). Accordingly, it was shown that in aged animals, A2AR-dependent glutamate release becomes 
more pronounced and shifts from a PKC-mediated signalling to a PKA-dependent effect (Lopes et 
al., 1999), which is accompanied with behavioural deficits in hippocampal-dependent tasks 
(Diógenes et al., 2011). 
Nonetheless, the mechanism involved in this A2AR upsurge and which exactly are the 
neurotransmitters or neuronal pool directly affected are yet unknown. This process can be seen as 
a result of a physiological stress condition, being a compensatory mechanism to offset the loss of 
efficiency of functioning of brain circuits (Rosenzweig & Barnes, 2003), namely through the increase 
of acetylcholine release. However, this could also result in excitotoxicity phenomena, by the 
promotion of glutamate release and GABA transmission, which could lead to the inhibition of 
hippocampal interneurons, thereby reinforcing glutamatergic action. Nevertheless, it is interesting to 
notice that this changes concerning adenosine receptor system in aged animals are similar to that 
found on noxious brain conditions, which rises an early-aging hypothesis behind neurodegeneration 
( Cunha, 2005; Batalha et al., 2013). 
 
1.3 | Rat Model of A2AR Overexpression (Tg(CaMKII-hA2AR)) 
In order to overcome current limitations that difficult proper investigation on the dysregulation of 
hippocampal A2AR function, transgenic rats that overexpress human A2AR driven by the CaMKIIα 
promoter have been generated (Tg(CaMKII-hA2AR)). The latter allows a profile of postnatal 
overexpression conditional to the glutamatergic forebrain neurons – mainly in the hippocampus and 
cortex – having very restricted expression in other areas (Coelho et al., 2014), with protein levels 
that are comparable to that found in physiological aging, without affecting A1R levels. 
Consequently, this animal model displays age-like alterations in hippocampal function, with 
cognitive, synaptic and molecular impairments. At the synaptic level, an increase in neuronal A2AR 
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is sufficient to increase glutamate release probability and intracellular Ca2+ levels, as well as to 
enhance synaptic NMDAR currents and decrease AMPAR currents, causing a shift in LTP/LTD 
probability (Temido-Ferreira et al., 2015). Accordingly, these alterations in synaptic function drive an 
impairment in hippocampal-dependent tasks both in spatial memory and short-term reference 
memory. 
All gathered, these features and their reversal by blocking A2AR activation strongly support the 
hypothesis that A2AR dysregulation drives synaptic dysfunction leading to cognitive impairments in 
hippocampal aging. 
 
1.4 | Glia and A2AR dysregulation 
Considering that any interference at the functional level of glial cells may create conditions 
favouring the development of degenerative processes, the key position of adenosinergic system in 
the control of glial function (Daré et al., 2007) has received increasing attention as a potential target 
in the modulation of neurodegenerative diseases, allowing to interfere at different components of the 
pathological condition, slowing down their progression (Fredholm et al., 2005). 
  
1.4.1 | Microglia 
Along the past years, growing evidence have generated new links between the brain and immune 
system, suggesting their intricate connection and significant crosstalk, both in the maintenance of 
homeostasis and in the progression of aging and neurodegenerative diseases (Lucin & Wyss-Coray, 
2009). 
Microglia, a cellular subset derived from myeloid precursors, are the gatekeepers of CNS 
immunology, establishing its first line of defence. Constituting approximately 10% of the total 
population of glial cells in the adult, their density varies considerably with anatomical region, ranging 
from a high of 12% in the basal ganglia to a low of 5% in the cortex of mice (Lawson et al., 1992). 
Considered to be the most susceptible sensors of brain pathology, microglial cells are endowed with 
numerous receptors capable of detecting physiological disturbances and continuously survey the 
entire brain parenchyma by constant extension and retraction of their thin and highly branched 
processes. Moreover, through a large number of signalling pathways, they are also able to 
communicate with neurons, astrocytes and immune cells, being key players of a functional 
neuroimmune interplay (Kettenmann et al., 2011). Therefore, through the integration of multifarious 
input signals, microglial cells display an extraordinary ability to respond rapidly and perform a broad 
range of functions in the modulation of CNS environment, from secretion of cytokines and 
chemokines which regulate the state of inflammation, to the release of mediators that control 
synaptic transmission, and phagocytosis of cells or cellular elements (Tambuyzer et al., 2009).  
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Following the detection of pathogens, brain lesion or nervous system dysfunction, microglia 
undergo a complex, multistage activation process that consists of a morphological transformation 
from a ramified to amoeboid appearance, in which these cells reduce the complexity of their shape 
and acquire characteristics resembling peripheral macrophages. Several steps and intermediate 
stages can be identified, including features of process withdrawal, transition or hyperramification, 
reflecting the high morphological plasticity of this cell subset and its functional adaption to its 
microenvironment (Kettenmann et al., 2011; Olah et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 - Schematic representation of microglial activation as a complex, multistage process. Cells can commit 
to distinct reactive phenotypes depending on the challenging stimuli and situational context (from Kettenmann et al., 2011) 
 
Depending on the interpretation of a given insult, microglia can acquire a “classically activated” M1 
phenotype - characterized by the secretion of proinflammatory mediators such as Tumor Necrosis 
Factor α (TNFα) or IL-1β, Nitric Oxide (NO), and glutamate – or an “alternatively activated” M2 
phenotype with the expression of anti-inflammatory factors - IL-4 and IL-13, for instance - which can 
enhance neuronal survival (Ji et al., 2013). Accordingly, M1 microglia have been associated with 
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neurotoxic and neurodegenerative processes, as it has been reported in cases of AD (Mandrekar-
Colucci et al., 2012), Amyotrophic Lateral Sclerosis (Liao et al., 2012), Multiple Sclerosis (Gao & 
Tsirka, 2011), Stroke and Traumatic Brain Injury (Hu et al., 2012; Kumar et al., 2013), whereas a 
shift to an M2 phenotype has been correlated with neuroprotection, recovery and repair in various 
disease contexts (Mikita et al., 2011; Wu et al., 2012; Shechter & Schwartz, 2013). 
 
Table 1.1: Cytokines produced upon microglial activation (adapted from Tambuyzer et al., 2009) 
 
 
Cytokines 
 
IL-1α/β IL-16 
IL-3 
IL-4 
IL-5 
IL-6 
IL-8 
IL-10 
IL-12 
IL-13 
IL-15 
IL-17 
IL-18 
IL-23 
IL-27 
TNF-α 
TGF-β 
IFN-γ 
GM-CSF 
M-CSF 
Abbreviations: IL- Interleukin; TNF- Tumor Necrosis Factor; TGF – Transforming Growth Factor; GM-CSF – Granulocyte-Macrophage 
Colony-Stimulating Factor; M-CSF - Macrophage Colony-Stimulating Factor. 
 
Due to the complexity of microglial cells and their high morphological and functional plasticity, 
histological approaches in conjunction with flow cytometry are critical to perform a full phenotypic 
characterization.  
As a result of their myeloid lineage, the lack of specific microglial-only antigens has hampered 
microglial identification, since markers used for the detection of microglia are also present in 
macrophages. Consequently, microglial cells can be identified by a variety of cell surface-associated 
or intercellular/cytosolic molecules, concerning receptors, adhesion molecules and enzymes 
(Kettenmann et al., 2011; Hooper & Pocock, 2015), as resumed in Table 1.2. 
Noteworthy, antibodies against Iba1 have proven most helpful in visualizing microglia with details 
of their processes (Kettenmann et al., 2011), while CD45lowCD11b/c+ phenotype has been proven to 
describe ramified parenchymal microglia (Ford et al., 1995), which justifies the preferential use of 
these markers in the identification of this cellular subset. Nonetheless, the functional changes 
inherent to the activation process upregulate the expression level of many of these molecules, such 
as CD11b (Roy et al., 2006) and Iba1 (Ito et al., 2001), with reactive microglia expressing MHC class 
II antigens, CD40, CD54, CD68, CD80/86 and other surface molecules necessary for antigen 
presentation and phagocytosis (Kettenmann et al., 2011; Ford et al., 1995; Hooper & Pocock, 2015; 
Sedgwick et al., 1991). 
Table 1.2: Principal microglial markers (Adapted from Kettenmann et al., 2011; Tambuyzer et al., 2009) 
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Molecular Structure/Antigen 
 
Properties and Functional Relevance 
 
CD11b/18 (αMβ2 integrin) 
 
Complement receptor 3 (CR3) 
CD11c (integrin αX) Cell adhesion 
CD16/32/64 (FcγRIII/II/I) Immunoglobulin Receptors 
CD34 Roles in adhesion, marker for precursor cells of myeloid 
origin 
CD40 Tumor Necrosis Factor (TNF) Receptor 
CD45 (Leucocyte Common Antigen) Transmembrane protein tyrosine phosphatase 
CD54 (Intracellular Adhesion Molecule 1) Stabilization of cell-cell interactions 
CD68 Phagocytosis 
CD80/86 (B7.1/B7.2) Antigen Presentation 
CD200R Myeloid cell inhibitory signalling 
Important for neuron-microglia communication 
CX3CR1 Fractalkine (CX3CL1) receptor 
Control of microglial activity (neuron-microglia 
communication) 
F4/80 Suggested role in immune tolerance 
Iba1 (Ionized Calcium-binding adaptor molecule 1) Suggested role in calcium homeostasis 
iNOS (inducible NO synthase) Enzymatic synthesis of NO from arginine during 
inflammation 
MHC I/ II Antigen presentation 
 
Microglial activation is also highly influenced by neurons, through ‘on’ and ‘off’ signals, which are 
responsible for an inhibitory feedback in the absence of neuronal damage (Biber et al., 2007). This 
signalling system involve several ligands and receptors – CX3CL1-CX3CR1, CD200-CD200R, 
CD47-CD172a, for instance – that allow CNS to actively control local immune responses, modulating 
microglia number, activation and recruitment to sites of injury (Cardona et al., 2006; Olah et al., 
2011). 
Moreover, microglia are also considered to be active contributors in a paradigm of “quad-partite 
synapse” either through direct action on neurons or indirectly via astrocytes. Synaptic activity can 
alter microglial functioning in several aspects, including membrane potential, intracellular calcium, 
cytokine release and overall cellular motility, due to their ability to express receptors for and respond 
to neurotransmitters such as glutamate, GABA, acetylcholine, and purines, including adenosine and 
ATP (Schafer et al., 2013; Kettenmann et al., 2011; Pocock & Kettenmann, 2007). Conversely, in 
addition to their capacity to rapidly modulate their dynamics in response to neurotransmission, 
evidences also suggest an important role in the regulation of synaptic transmission (Ji et al., 2013; 
Schafer et al., 2013). Particularly in the hippocampus, several associations between soluble factors 
released by microglia and actions upon basal transmission and synaptic plasticity have been 
demonstrated, namely relating the secretion of Glycine and L-serine to the enhancement of LTP and 
NMDA receptor-mediated responses (Moriguchi et al., 2003; Hayashi et al., 2006), a link between 
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TNF-α and synaptic scalling (Stellwagen & Malenka, 2006) and a relation between ATP release and 
the modulation of basal glutamatergic transmission (Pascual et al., 2012). Lastly, besides synaptic 
plasticity, microglia also play dynamic roles at developing and mature synapses by the remodelling 
and maturation of synaptic circuits, being crucial to normal brain wiring and function (Schafer et al., 
2013; Santiago et al., 2014). Therefore, this ability to shape neuronal environment according to the 
functional state of synapses through phagocytosis of synaptic elements, together with their role in 
the modulation of neurotransmission highlight the relevance of microglia as promotors of the 
homeostasis and long-term stability of neural networks. 
The process of neuroinflammation is known to contribute to the exacerbation of neuronal damage. 
In fact, contexts of neurodegeneration are bolstered by dysregulation of microglial function, 
presenting features of abnormal synaptic transmission, aberrant synapse formation and/or 
elimination and abnormal phagocytosis as pathological hallmarks. Accordingly, increased levels of 
activated microglia have been correlated with most noxious brain conditions (Cunha, 2005) and 
degenerated brain regions in animal models and post-mortem examination of cases of AD and 
Parkinson’s Disease (PD) (McGeer et al., 1987, 1988; Su et al., 2008). In agreement, the blockade 
of microglia-induced neuroinflammation has been proven to attenuate neurodegeneration (Santiago 
et al., 2014), which further supports their involvement in the evolution of the pathological process. 
Consistent with the known ability of A2AR to control the activation of different inflammatory cell 
types, an increase in the expression of A2AR by microglial cells following their activation have been 
reported upon different brain insults (Canas et al., 2004; Yu et al., 2008). The hypothesis of A2AR 
modulation of microglia-induced neuroinflammation, controlling the genesis of the 
neuroinflammatory feedforward loop that leads to neurodegeneration, synaptic and cognitive 
impairments is supported by several studies in which A2AR blockade is sufficient to abrogate the 
Lipopolysaccharide (LPS)-induced microglial activation and consequent neuronal dysfunction 
(Rebola et al., 2011), reduce microinflammation in different pathological conditions (Laurent et al., 
2014; Yu et al., 2008; Dai et al., 2010), improve microglia response to tissue damage and reduce 
cognitive impairments in AD and PD animal models (Gyoneva et al., 2014; Arendash et al., 2009; 
Ferreira et al., 2015). Therefore, therapeutic approaches of neuroinflammation modulation may 
represent a strategy for the attenuation of the neurological impairment underlying 
neurodegeneration, exploring the functional interplay between A2AR and microglial cells. 
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1.4.2 | Astrocytes 
Astrocytes are the most abundant and heterogeneous cell type in the CNS, being responsible for 
the promotion of homeostasis through a wide range of essential complex functions (Sofroniew & 
Vinters, 2010). Occupying 25% to 50% of brain volume (Magistretti & Ransom, 2002), their star-
shaped morphology provides structural support to the CNS, forming the infrastructure on which other 
cells are anchored. Astrocytic multiple fine processes intertwine with neurons, ensheath dendrites 
and synapses and surround brain capillaries, integrating neuro and vascular elements within an 
individual astroglial territorial domain, thereby dividing brain parenchyma into independent 
neurovascular units (Kettenmann & Verkhratsky, 2011). 
 
In addition to their structural role, astrocytes support and modulate synaptic transmission by means 
of numerous coordinated mechanisms. Through the expression of functional neurotransmitter 
receptors (glutamate, ATP, GABA, acetylcholine or endocanabinoids) (Oberheim et al., 2012),  
information shared inside and outside synapses is continuously sensed and elicits astrocytic calcium 
signalling, promoting the release of neuro and vasoactive substances - such as glutamate, D-serine, 
ATP, GABA, TNF-α, prostaglandins and peptides - which lead to feedback regulation of neuronal 
activity, synaptic strength, blood flow and metabolism, in a process known as gliotransmission 
(Stehberg et al., 2012). Moreover, astrocytic network is also crucial in spatial buffering of K+ and 
regulation of ion concentrations, as well as in neurotransmitter homeostasis, by ensuring glutamate-
glutamine turnover, contributing to an overall neuronal protection against excitotoxicity (Magistretti 
& Ransom, 2002; Pekny et al., 2016). 
Furthermore, reactive astrocytes are critical for tissue repair and function maintenance in the CNS. 
Following brain insults, astrocytes undergo a multicomponent activation process designated 
astrogliosis which consists on a continuum of complex changes that occur in a context-dependent 
manner, leading to profound changes in astrocytic biochemistry and physiology, by activation of 
pathways involved in inflammation, metabolism, cytoarchitecture and microenvironmental regulation. 
Thus, reactive astrocytes acquire the ability to release diverse molecular signals, both anti- and pro-
inflammatory factors, capable of affecting the activity of different types of surrounding cells, in an 
attempt to increase neuroprotection (Pekny et al., 2016; Sofroniew & Vinters, 2010) (Figure 1.3). 
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Figure 1.3: Schematic representation of molecular 
signals sent by reactive astrocytes. Reactive astrocytes 
establish complex signalling interactions with different cell 
types through the release of numerous growth factors, 
neurotransmitters, cytokines and chemokines (from Pekny 
et al., 2016) 
 
 
Although reactive astrogliosis is protective in acute responses, limiting the extent of 
neurodegeneration, if it persists, long-lasting scar formation might be promoted, along with a shift 
towards a pro-inflammatory and potentially cytotoxic phenotype, resulting in permanent 
rearrangement and insult of brain parenchyma (Pekny et al., 2016; Sofroniew & Vinters, 2010). 
Actually, dysfunction or maladaptative responses of astroglia are known features of 
neurodegenerative processes, contributing and exacerbating the progression of several diseases. 
At a neuropathological level, astrocyte changes are highly variable and disease specific, concerning 
phenotypes of exarbated astrogliosis response, pathological remodeling and atrophy with loss of 
function, which can be simultaneously present or emerge sequentially with disease progression 
(Pekny et al., 2016; Maragakis & Rothstein, 2006) (Figure 1.4) 
 
 
 
 
 
 
 
 
 
Figure 1.4 -  Schematic representation of pathological changes in astroglia. Astroglial component of 
neuropathology is highly variable and is often disease specific (from Pekny et al., 2016) 
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The complex process of astrogliosis can be induced and directly modulated by a broad range of 
extracellular molecules, from purines, neurotransmitters and steroid hormones to growth factors, 
cytokines, serum proteins or neurodegeneration-associated molecules (Pekny et al., 2016). In fact, 
adenosine and A2AR can modulate astrocytic function both through the control of astrogliosis and 
consequent release of different substances that influence synaptic activity, or by an indirect fine-
tuning of the action of other receptor systems in astrocytes (Daré et al., 2007). As A2AR activation 
can inhibit EAAT2-mediated astrocytic glutamate uptake and enhance glutamate release (Cunha, 
2005), the detrimental effects of high levels of adenosine deriving from prolonged or exaggerated 
exposure to noxious brain conditions are also result of an inflicted dysregulation of astroglial function. 
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2 | AIMS 
Noxious brain conditions such as hypoxia, ischemia, epilepsy, stress or aging are known to induce 
an inbalance of adenosinergic system, characterized by a long term robust upregulation of A2AR in 
cortical and hippocampal regions, which leads to excitotoxicity, dendritic retraction and memory and 
synaptic plasticity impairment. Although the mechanism involved in this A2AR upsurge and which 
exactly are the neurotransmitters or neuronal pool directly affected are yet unknown, different studies 
have been linking this changes concerning adenosine receptor system upon brain insults with those 
found in aged animals, raising an early-aging hypothesis behind neurodegeneration. 
Having as hypothesis that A2AR dysregulation in the genesis of synaptic dysfunction and cognitive 
impairments in hippocampal aging derives from glutamatergic neurons, transgenic rats with a 
postnatal A2AR overexpression conditional to the glutamatergic forebrain neurons (Tg(CaMKII-
hA2AR), have been generated. Since this animal model displays age-like alterations in hippocampal 
function, with cognitive, synaptic and molecular impairments, it constitutes an unprecedented model 
to detail A2AR dysregulation in the hippocampus. 
Therefore, this study aimed to evaluate the contribution of different cellular subsets to the 
pathological phenomena associated with A2A receptors dysregulation in the hippocampus.  
As the modulatory potential of adenosine is also extended to the control of glial cell function, it was 
assessed if this neuronal-specific overexpression of A2AR drives alterations in the reactivity 
of astrocytes and microglia, exploring the contribution of these cells to the hippocampal 
dysfunction. Moreover, it was also aimed to assess impacts on hippocampal circuitry, analyzing 
secondary effects of a glutamatergic-specific A2AR overexpression. 
Clarifying the involvement of different cellular subsets in the A2AR dysregulation underlying synaptic 
and cognitive dysfunction will be helpful to improve knowledge of neuropathology, including aging 
and neurodegeneration. 
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3 | METHODS 
3.1 | Animals 
Animal procedures were performed within the rules of the Portuguese official veterinary 
department, which complies with European Directive 2010/63/EC and the Portuguese law 
transposing this Directive (DL 113/2013), and approved by the Instituto de Medicina Molecular 
Internal Committee and the Portuguese Animal Ethics Committee (Direcção Geral de Veterinária). 
Environmental conditions were kept constant: food and water ad libitum, 21±0.5°C, 60±10% relative 
humidity, 12 h light/dark cycles.  
A model of transgenic rats that overexpress A2AR - Tg(CaMKII-hA2AR) - was used, as described in 
Coelho et al. (2014). These were generated by microinjection of a linearized DNA construct 
(Supplementary Figure 7.1) into male pronucleus of Sprague-Dawley rat zygotes, consisting on a 
full-length human A2A cDNA cloned into an expression vector with the 8.5kb mouse CaMKIIα 
promoter and a polyadenylation cassete of bovine growth hormone. Littermate WT animals were 
used as controls. 
 
3.2 | Genotyping 
Transgenic rats were identified by Polymerase Chain Reaction (PCR) (30 cycles, 58ºC annealing 
temperature) of their genomic DNA isolated from ear biopsies by the use of transgene-specific 
primers: CaMKII-hA2AR and rat β-actin (Invitrogen, Table 3.1) 
 
Table 3.1 - Primers used for genotyping of transgenic animals 
 
Primer Target Gene Organism Forward Primer Reverse Primer Amplicon 
Size 
 
Act-B 
 
β-actin 
 
Rat 
 
AGCCATGTACGTAGCCAT 
 
CTCTCAGCTGTGGTGGTGAA 
 
228 bp 
CaMKII-
hA2AR 
 
Calcium 
calmodulin-
dependent Protein 
Kinase II promoter   
and human 
Adenosine A2A 
Receptor 
Transgene GACTAAGTTTGTTCGCATCCC GTGACACCACAAAGTAGTTGG 450 bp 
 
3.3 | Hippocampal Cell Dissociation 
Based on Kay & Wong (1986), animals with about 8 weeks old were decapitated under deep 
anesthesia by Isofluorane, hippocampi were removed and sliced at 650µm thickness with a McIlwain 
tissue chopper. CA1 and CA3 regions of 6 slices per hippocampus were dissected and incubated at 
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32ºC for 5 minutes in an oxygen saturated dissociation solution (120mM NaCl, 5mM KCl, 1mM 
CaCl2, 1mM MgCl2, 25mM Glucose and 20mM PIPES) with 0.2mg/ml of Proteinase K, followed by 
a 30 minutes incubation at 32ºC with 1mg/ml Trypsin diluted in oxygen saturated dissociation 
solution. 
After chemical dissociation, slices were transferred to an oxygen saturated enzyme-free 
dissociation solution, briefly washed, and each slice was mechanically dissociated in 1ml of 
Dulbecco's Modified Eagle's Medium (DMEM) (Gibco – Life Technologies) by gentle trituration, using 
2 fire polished Pasteur pipettes (1 and 0.2 mm bore). Immediately after trituration, 500µl of 
supernatant was plated per well on poly-D-lysine-coated coverslips in 24-well plates, and incubated 
for 30 minutes to promote cell decantation. After removing medium from wells, immunocytochemistry 
protocol was performed. 
 
3.4 | Primary Neuronal Cultures 
Primary rat neuronal cultures were obtained from 18 days rat embryos, according to Pedersen et 
al (2002). Brieﬂy, a pregnant rat, previously genotyped as Transgenic (Tg(CaMKII-hA2AR)) was 
decapitated under deep anesthesia with Isofluorane. The embryos were collected in Hanks’ 
Balanced Salt Solution (HBSS) (Corning) and rapidly decapitated. Meninges were removed, whole 
cortices (hippocampi and attached cortex) dissociated and incubated for 15 minutes in HBSS with 
0.025% trypsin. Cells were washed once with HBSS with 30% Fetal Bovine Serum (FBS), 
centrifuged three times, re-suspended in Neurobasal Medium (Gibco – Life Technologies) 
supplemented with 2% B-27 supplement, 25 µM Glutamate, 0.5 mM glutamine, and 2 U/ml 
Penicillin/Streptomycin, gently dissociated and filtered through a 70µm strainer (VWR). 
After counting, cells were plated on poly-D-lysine-coated coverslips in 24-well plates at density of 
8x104 cells/well. Neurons were grown at 37°C in a 5% CO2 humidiﬁed atmosphere in the previously 
described supplemented Neurobasal medium, in the absence of any positive selection for neurons. 
Medium was not replaced and cultures were used at day 9 and 14. 
 
3.5 | Immunocytochemistry 
Cells from either hippocampal dissociation or primary neuronal cultures were fixed for 10 minutes 
with 4% Paraformaldehyde (PFA) diluted in Phosphate Buffer Saline (PBS) (Alpha Aesar). After 
washing thrice with PBS, cells were permeabilized for 10 minutes with 0.05% Triton-X in PBS, 
blocked for 30 minutes with 10% FBS in PBS and incubated overnight at 4°C with primary antibodies 
diluted in PBS with 0.05% Tween-20 and 4% FBS (Table 3.2). 
After washing three times with PBS with 0.05% Tween-20, cells were incubated for 1 hour with 
secondary antibodies diluted in PBS with 0.05% Tween-20 and 4% FBS (Table 3.2). In order to label 
cell nucleus, after washing 30 minutes with PBS with 0.05% Tween-20, coverslips were incubated 
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for 5 minutes with Hoechst (Hoechst 33342, Thermo Scientific; 12µg/ml final concentration) and 
washed for 30 minutes with PBS 0.05% Tween-20. After a final washing step with PBS, coverslips 
were mounted with Dako Fluorescent Mounting Medium (Dako) and let to dry for 24h at room 
temperature, protected from light exposure. 
Cells were observed either with a Zeiss Axiovert 200M Fluorescence Microscope or a Zeiss LSM 
710 Confocal Microscope. 
 
Table 3.2 - Primary and secondary antibodies and related conditions used in the Immunocytochemistry experiments.  
All antibodies were diluted in PBS with 0.05% Tween-20 and 4% FBS 
 
Protein 
Primary 
Antibody 
Host Dilution 
 
Secondary 
Antibody 
(from Life Technologies) 
Dilution 
A2AR 
 
Santa Cruz 
Biotechnologies 
(SC-7502) 
 
Goat 1:100 
 
 
Alexa Fluor 633 donkey anti-goat  
 
 
Alexa Fluor 568 donkey anti-mouse 
Alexa Fluor 488 goat anti-mouse 
IgG2a (γ2a) 
 
 
Alexa Fluor 488 donkey anti-rabbit 
 
 
Alexa Fluor 568 donkey anti-mouse 
 
Alexa Fluor 488 donkey anti-rabbit  
 
A2AR 
Millipore 
(clone 7F6-G5-A2) 
 
Mouse 1:100 
FLAG 
Sigma-Aldrich 
(F7425) 
 
Rabbit 1:200 
MAP-2 
Millipore 
(05717) 
 
Rabbit 1:200 
SYP 
Sigma-Aldrich 
(S5768) 
 
 
Mouse 1:250 
PSD-95 
 
Cell Signalling 
(D27E11) 
Rabbit 1:500 
 
Abbreviations: A2AR – Adenosine A2A Receptor; MAP-2 - Microtubule-associated protein 2; SYP – Synaptophysin; PSD-95 - Postsynaptic 
Density Protein 95 
 
3.6 | Brain Perfusion 
Animals with 12 to 14 weeks old were deeply anaesthetized with an Intraperitonial Injection of a 
mixture containing Ketamine and Xylazine (120mg/KgBW Ketamine + 16mg/KgBW Xylazine) and 
transcardially perfused via the ascending aorta. A lateral incision was made below the sternum and 
xiphoid process was held with forceps. The diaphragm was cut and an incision was made parallel to 
the sternum to expose the thoracic cavity. A needle was inserted into left ventricle, and the right 
atrium perfurated to initiate perfusion. Animals were perfused with 200ml of a 0.9% NaCl solution 
and subsequently perfused with 500ml of 4% PFA diluted in PBS. After perfusion, animals were 
decapitated, brains were removed and cryopreserved in a 15% sucrose in PBS solution overnight at 
4ºC, followed by 30% sucrose in PBS solution during 48h at 4ºC. 
1:400 
 
1:500/1:1000 
 
1:400 
1:400 
 
1:400 
 
1:400 
1:400 
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3.7 | Gelatin Embedding 
After cryopreservation in 15 and 30% sucrose, brains were equilibrated with a 15% sucrose/7.5% 
gelatin in PBS solution for 1h at 37ºC, embeded in the same solution and left to solidify overnight at 
4ºC. The included tissue was cut into blocks and slowly frozen to -70ºC by submerging in isopentane 
cooled with liquid nitrogen. The blocks were kept at -80ºC until use. 
 
3.8 | Immunohistochemistry 
Coronal cryostat sections of 12µm - starting at approximately -3.14mm from Bregma - were 
collected with a CM3050S Leica cryostat and mounted in Superfrost Slides (Thermo Scientific). 
For immunohistochemistry, the slides were incubated in PBS for 10 minutes at 37ºC followed by a 
20 minutes incubation with 0.1M glycine in PBS. The slices were then permeabilized and blocked 
with a solution of TBST-T 0.2% (Tris Buffer Saline with 0.2% Tween-20 solution, 200nM Tris, 1.5 M 
NaCl) containing 10% FBS and 1% BSA (Bovine Serum Albumin) for 1 hour. Incubations with 
primary antibodies (Table 3.3) were performed for 48h at 4ºC and slices were washed for 30 minutes 
in TBS-T 0.1% (Tris Buffer Saline with 0.1% Tween-20 solution, 200nM Tris, 1.5 M NaCl) before 
being incubated overnight at 4ºC with secondary antibodies (Table 3.3). After a 30 minutes washing 
with TBS-T 0.1%, slices were incubated for 10 minutes with Hoechst (Hoechst 33342, Thermo 
Scientific; 12µg/ml final concentration) and washed for 15 minutes with PBS. Lastly, slices were 
mounted in Dako Fluorescent Mounting Medium (Dako) and left to dry for 24h at room temperature 
protected from light exposure. 
 
Table 3.3  Primary and secondary antibodies and related conditions used in the Immunohistochemistry experiments. 
All antibodies were diluted in TBS-T 0.1% with 4% FBS. 
 
Protein 
Primary 
Antibody 
Host Dilution 
Secondary 
Antibody 
Dilution 
A2AR 
Santa Cruz 
Biotechnologies 
(SC-7502) 
Goat 1:100 
Abcam 
(Donkey anti-goat cy3) 
 
Life Technologies 
(Alexa Fluor 633 donkey anti-goat, 
Alexa Fluor 568 donkey anti-mouse 
Alexa Fluor 488 donkey anti-rabbit 488) 
 
1:400 
 
 
1:400 
 
 
 
FLAG Sigma-Aldrich 
(F7425) 
Rabbit 1:200 
Iba1 
 
Abcam 
(ab5076) 
Goat 1:200 
GFAP 
 
Millipore 
(MAB360) 
Mouse 1:250 
SYP Sigma-Aldrich 
(S5768) 
Mouse 1:250 
PSD-95 
 
Cell Signalling 
(D27E11) 
Rabbit 1:400 
Abbreviations: A2AR – Adenosine A2A Receptor; Iba1 - Ionized Calcium-Binding Adapter Molecule 1; GFAP - Glial Fibrillary Acidic Protein; 
SYP – Synaptophysin; PSD-95 - Postsynaptic Density Protein 95  
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3.9 | DNA extraction and sequencing 
DNA was extracted using NucleoSpin Gel and PCR Clean-Up Kit (Macherey-Nagel). Briefly, after 
electrophoresis of PCR products of genotyping procedure, 2 bands of agarose gel containing the 
450 bp fragment amplified using CaMKII-hA2AR specific primers (see Table 3.1) were excised. 
After agarose was dissolved, samples were loaded into a column and centrifuged twice for 30 
seconds at 11000 xg, in order to bind DNA to a silica membrane and to promote its washing. Then, 
the membrane was dried and DNA eluted. Lastly, DNA was analyzed with Nanodrop 2000 
Spectrophotometer (Thermo Scientific) and sent for sequencing (GATC Biotech) using CaMKII-
hA2AR specific primers at a 5µM concentration. 
 
3.10 | Sample preparation for Western Blotting 
Frozen hippocampal tissue was placed in 400µl of RIPA (Radio-Immunoprecipitation-Assay) buffer 
(50mM Tris, 1mM EDTA, 150mM NaCl, 0.1% SDS, 1% NP-40, pH 8) and homogenized by 
sonication. Protein was quantified using the BioRad DC Protein Assay Kit, based on Lowry (1951), 
due to the high levels of detergents in the sample. 
After protein quantification, the appropriate volume of each sample was diluted in four volumes of 
water and one volume of sample buffer (350 mM Tris pH 6.8, 30% glycerol, 10% SDS, 600 mM DTT 
and 0.012% Bromophenol blue). The samples were denatured at 95°C for 5 minutes.  
 
3.11 | Western Blotting 
Based on the protocol of Towbin et al. (1979), samples and molecular weight markers were 
separated by SDS-PAGE electrophoresis in denaturing conditions, using 5% stacking gel and either 
a 10% or 15% resolving gel, and electro-transferred to PVDF membranes (Millipore). Membranes 
were blocked with 3% BSA in TBS-T 0.1% for 1 hour and incubated with primary antibody (diluted 
in TBS-T with 3% BSA) overnight at 4°C in a roller. After washing with TBS-T for 30 minutes, the 
membranes were incubated with horseradish peroxidase (HRP, EC 1.11.1.7) conjugated secondary 
antibody in 5% non-fat dry milk for 1 hour at room temperature (primary and secondary antibody 
dilutions are in Table 3.4). After 30 minutes of washing with TBS-T, chemoluminescent detection 
was performed with ECL Western Blotting Detection Reagent (GE Healthcare) using X-Ray films 
(Fujifilm) developed in Curix 60 Processor (AGFA). Optical density was determined with ImageJ 
software and normalized to the respective GAPDH band density. 
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Table 3.4 - Primary and secondary antibodies and related conditions used in the Western Blotting experiments for 
individual proteins. All primary antibodies were diluted in TBS-T 0.1% with 3% BSA and secondary antibodies in 5% non-
fat dry milk diluted in TBS-T 0.1% 
 
Protein 
 
Protein 
Loading 
(µg) 
 
Resolving 
Gel 
(%) 
Primary 
Antibody 
Host Dilution 
Secondary 
Antibody 
Dilution 
FLAG 30 10 Sigma-Aldrich 
(F7425) 
 
Rabbit 1:320 
Santa Cruz 
Biotechnologies 
(Donkey anti-goat, 
Goat anti-mouse 
Goat anti-rabbit) 
1:10000 
Iba1 30 15 
 
Abcam 
(ab5076)  
Goat 1:500 
PSD-95 30 10 
 
Cell Signalling 
(D27E11)  
Rabbit 1:1000 
GFAP 30 10 
 
Millipore 
(MAB360) 
Mouse 1:1000 
SNAP-25 30 15 
 
Sigma-Aldrich 
(S9684) 
Rabbit 1:10000 
GAPDH - - 
 
Life 
Technologies 
(6C5) 
Mouse 1:1000 
 
Abbreviations: Iba1 - Ionized Calcium-Binding Adapter Molecule 1; PSD-95 - Postsynaptic Density Protein 95; GFAP - Glial Fibrillary 
Acidic Protein; SNAP-25 - Synaptosomal-Associated Protein 25; GAPDH - Glyceraldehyde 3-Phosphate Dehydrogenase 
 
3.12 | Analysis of Neuronal Cell Number 
Per animal, four fields of CA1 pyramidal cell layer were randomly selected of 12µm hippocampal 
slices and acquired at 40x magnification using a Zeiss Cell Observer Widefield microscope. Cells 
labeled with Hoechst were counted using Cell Counter Plugin of ImageJ software. 
 
3.13 | Morphological analysis of microglial cells 
Confocal Z-stacks of 12µm slices stained with Iba1 were taken at 20x magnification, using a Zeiss 
LSM 710 Confocal Microscope. 
Based on Almolda et al. (2015), a morphometric analysis of Iba1 labeled microglia was performed. 
For each animal, a total of 60 representative microglial cells from CA1 area were chosen from a 
minimum of 10 different z-stack images. Using ImageJ software, maximum intensity projection 
images were generated and individual cells were isolated by the tracing of their perimeter with 
Polygon Selection tool. Different parameters including the fitted ellipse were recorded for each cell. 
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3.14 | Flow Cytometry 
After deep anesthesia with Isofluorane, rats were perfused with approximately 200ml of PBS via 
the left ventricle of the heart to exclude circulating and nonadherent erythrocytes and leukocytes 
from the brain. Brains were removed, hippocampi were dissected on ice-cold Krebs Buffer (124mM 
NaCl, 3mM KCl, 1.25mM Na2HPO4, 26mM NaHCO3, 1mM MgSO4, 2mM CaCl2, 10mM glucose) and 
minced with a razor blade in ice-cold GKN/BSA Buffer (GKN: 8g/l NaCl, 0.4g/l KCl, 3.6g/l 
Na2HPO4.12H2O, 0.8g/l NaH2PO4, 2g/l D-(+)-glucose, 0.3% BSA, pH 7.4, 4ºC). 
Two experimental conditions were performed. Firstly, according to Doorn et al. (2015), identical 
regions of 2 animals were pooled per experiment to increase microglial yield and tissue was gently 
dissociated in GKN/BSA Buffer, mashed through a 70µm pore size strainer (VWR) to reach a single 
cell suspension and centrifuged for 10 minutes at 300g at 4ºC. The supernatant was discarded and 
the remaining cell pellet was resuspended in 1ml of 50% Percoll diluted in GKN/BSA buffer, after 
which an additional 7ml 50% Percoll was added. Then, 4ml of 75% Percoll was gently under layered 
and subsequently 3ml GKN/BSA buffer was layered on top of the 50% Percoll layer. The Percoll 
gradient was centrifuged at 1300 xg, for 30min at 4ºC, with minimum acceleration and brakes off. 
After the removal of the top layer - composed of thick, viscous myelin – the interphase between the 
50 and 75% Percoll was carefully removed using a Pasteur pipette, washed with GKN/BSA buffer 
and cells were resuspended in PBS buffer. 500µl aliquots of cell suspension were prepared and 
incubated for 30 minutes with FITC-conjugated anti-integrin αM/CD11b (OX42) antibody (Santa Cruz 
Biotechnologies, sc-53086, final dilution 1:200) and PE-conjugated anti-CD45 (OX30) antibody 
(Santa Cruz Biotechnologies, sc-53047, final dilution 1:200) at room temperature, in a rocker. Lastly, 
cells were rinsed in PBS, pelleted at 1200rpm for 5 minutes at 4ºC and ressuspended in 300µl PBS.  
In the second experimental condition, the previous protocol was maintained with the exception of 
Percoll gradient, in order to obtain non-purified samples. 
Data acquision was performed on a BDAccuri C6 Flow Cytometer (BD Biosciences) and analyzed 
using FlowJo software. 
 
3.15 | GFAP DAB Immunohistochemistry 
Coronal cryostat sections of 40µm - starting at approximately -3.14mm from Bregma - were 
collected with a CM3050S Leica cryostat and mounted in Superfrost Slides (Thermo Scientific) with 
intervals of 160µm, in order to obtain a set of non-contiguous serial sections spanning dorsal 
hippocampus. 
Gelatin was removed from slices by incubation with PBS for 10 minutes at 37ºC. Staining was 
preformed using the EnVision+ System-HRP (DAB) from Dako. After washing 1 hour with Wash 
Buffer at room temperature, peroxidase was blocked with 3% H2O2 in methanol for 30 minutes. 
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Following washing 15 minutes with Wash Buffer, slices were blocked with Protein-Block for 40 
minutes and incubated with Rabbit anti-GFAP polyclonal antibody (Dako) at a 1:500 dilution, for 2 
hours at room temperature. After washing 15 minutes with Wash Buffer, slices were incubated with 
Anti-Rabbit antibody conjugated with HRP (Dako) for 1 hour at room temperature, and washed for 
15 minutes washing with Wash Buffer. Slices were then stained with 3,3'-Diaminobenzidine (DAB) 
for 2 minutes and rinsed in distilled H2O (dH2O). Lastly, slices were dehydrated using a graded series 
of Ethanol (70%, 96%, 100%), cleared in Xylene and mounted. 
 
3.16 | Morphological analysis of astroglial cells 
Based on Morel et al. (2015), per animal, a set of three non-contiguous 40µm coronal cryostat 
sections was processed by GFAP DAB Immunohistochemistry and scanned with a NanoZoomer SQ 
slide scanner (Hamamatsu) under 20x magnification. In each set, a total of 90 representative GFAP+ 
cells of CA1 area were randomly chosen and analyzed using Sholl Analysis Plugin v1.0 of ImageJ 
software. This technique consists of individualizing cells by precise drawing and superimposing a 
grid with concentric rings distributed at equal distances centered on cell body. The number of 
process intersections per shell was then computed in order to evaluate length and complexity of 
astroglial branching. 
 
3.17 | Statistics 
GraphPad Prism 5 software was used for statistical analysis. The values presented are mean 
±SEM of n experiments. To test the significance of differences between WT and Tg(CamKII-hA2AR), 
unpaired Student’s t-test was used. In the morphological analysis of astroglial cells, a two way 
ANOVA followed by a Bonferroni’s Multiple Comparison post hoc test was used. Values of P<0.05 
were considered to be statistically significant.  
 
 
  
 31 
 
4 | RESULTS 
4.1 | Localization and secondary effects of A2AR overexpression 
Previous results from our group have characterized the molecular features of the CaMKII-hA2AR 
transgenic model (Supplementary Figure 7.5), confirming that these animals overexpress A2AR 
mostly in the hippocampus, in the pre-synaptic region and from 2 weeks-old onwards. In sequence 
with this preliminary data, the current project had the purpose to investigate the localization of A2AR 
in Tg(CaMKII-hA2AR) rat model, as well as the consequences of this upsurge in the pattern of 
expression of A2AR in different cellular subsets. 
In order to do so, several approaches were possible, with advantages and disadvantages that were 
considered in the experimental strategy. Immunohistochemistry was the first method to be chosen, 
due to the advantage of preserving the structure of hippocampal tissue. 
A2AR signal consisted of a puncta-like staining around cell body of neurons in both conditions 
(Figure 4.1), not allowing to infer a viable conclusion, as the antibody used is not specific to the 
human subtype of A2AR. 
 
Figure 4.1 - A2AR staining by immunohistochemistry. Fluorescence immunohistochemistry images from CA1 area of 
12µm rat hippocampal sections at 40x magnification. Neuronal nuclei are stained with Hoechst (blue) and A2AR are 
identified by red fluorescence using goat anti-human A2AR antibody (Santa Cruz Biotechnologies). Scale Bar:25µm. 
With the intention of bypassing the difficulties inherent to A2AR antibodies, we tried to use the FLAG-
tag included in the construct that generated Tg(CaMKII-hA2AR) rats (Supplementary Figure 7.1) as 
a mean to locate transgenic A2AR receptor expression. Firstly, we extracted DNA from transgenic 
animals and sequenced the 450bp amplicon in order to assess if the FLAG-tag was successfully 
inserted in the transgene and correctly in fusion with the A2AR protein. Nonetheless, even though we 
confirmed that there is a FLAG epitope inserted in frame between 6 and 7th aminoacids of the N-
terminal of the transgenic human A2AR protein (Supplementary Figure 7.2), anti-FLAG antibody 
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also failed to detect A2AR overexpression by Immunohistochemistry and Western Blotting 
(Supplementary Figures 7.3 and 7.4). 
Considering that immunohistochemistry has the constraint of decreased epitope accessibility, 
primary neuronal cultures seemed a good alternative to promote antibody staining by enhancing 
epitope exposure. Thus, mouse anti-A2AR antibody (Millipore), goat anti-human A2AR antibody 
(Santa Cruz Biotechnologies) and rabbit anti-FLAG antibody (Sigma-Aldrich) were tested by 
Immunocytochemistry. The results obtained did not allow us to localize A2AR overexpression. 
However, it is difficult to recreate this model in primary neuronal cultures, since the overexpression 
of A2AR in transgenic animals is only post-natal (2 weeks-old onwards) and the progeny of 
heterozygous animals can lead to cultures with mixed genotypes, which can explain the lack of 
results. 
Alternatively, we attempted to label A2AR in fully differentiated cells isolated from hippocampus of 
adult animals through enzymatic and mechanical dissociation. Nevertheless, this method did not 
allow us to detect any specific A2A labelling, possibly reflecting an irreversible alteration of membrane 
channels by trypsin digestion, or a consequence of the loss of distal dentritic processes. 
Lastly, in collaboration with Neuropathology Department of Hospital de Santa Maria, A2AR staining 
was performed using mouse anti-A2A antibody (Millipore; clone 7F6-G5-A2) and HRP DAB detection 
and amplification systems, which enabled the detection of the human A2AR overexpression in CA3 
axonal projections and in the neuropil of DG and CA1 areas of Tg(CaMKII-hA2AR) animals (Figure 
4.2). 
 
 
Figure 4.2 - Distribution of human A2AR overexpression in Tg(CaMKII-hA2AR) rats. Staining was present in 
hippocampal and striatal areas of Tg(CaMKII-hA2AR) animals but not WT littermates. Within the hippocampus, positive 
labelling can be observed in CA3 axonal projections and strong staining is also observed in the neuropil of DG and CA1 
areas. Immunohistochemistry: brain tissue was fixed in formalin, processed, embedded and sectioned in paraffin. Coronal 
sections across the span of the brain were stained using a mouse anti-A2A antibody (Millipore; clone 7F6-G5-A2) and 
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revealed using HRP-DAB detection and amplification systems. Images were acquired with NanoZoomer SQ slide scanner 
(Hamamatsu) under 20x magnification. (Staining performed by Dr. Pedro Pereira, Neuropathology Hospital Santa Maria, 
Lisbon).  
 
4.2 | A2AR overexpression and neuronal loss 
In order to assess if A2AR overexpression in forebrain neurons was correlated with synaptic loss, 
the number of neuronal cells in pyramidal layer of CA1 area and the levels of markers of synaptic 
density in the hippocampus were evaluated in CaMKII-hA2AR transgenic model. 
 
4.2.1 | Neuronal cell counts in CA1 area 
No significant differences were found in neuronal cell number of CA1 pyramidal layer in four 
randomly selected 40x fields of Tg(CaMKII-hA2AR) (n=3) and WT littermates (n=2) (P>0.05) (Figure 
4.3). 
 
 
Figure 4.3 - Neuronal cell number in the CA1 area of hippocampus. Four fields of 40x magnification were randomly 
selected and analyzed per each WT (black) (n=2) or Tg(CaMKII-hA2AR) (white) (n=3) animals. Results are presented as 
the mean ± SEM. At the right, representative images of neuronal nuclei stained with Hoechst are presented. Scale Bar: 
25µm. 
 
4.2.2 | Levels of markers of synaptic density 
Synaptosomal-associated protein 25 (SNAP-25), a component of the SNARE complex, is a 
presynaptic plasma membrane protein involved in regulation of neurotransmitter release (Hodel, 
1998). The levels of SNAP-25 were quantified by Western Blotting to assess presynaptic density.  
Hoechst 
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Results revealed no significant changes in protein levels of SNAP-25 in Tg(CaMKII-hA2AR) (n=7) 
compared to WT littermates (n=7) (P>0.05) (Figure 4.4). 
 
 
Figure 4.4 - SNAP-25 levels in the rat hippocampus. Immunoreactivity of SNAP-25 was measured in whole tissue 
homogenates either for WT (black) or Tg(CaMKII-hA2AR) (white) animals. Specific immunoreactivity was normalized to that 
of GAPDH. Results are the mean ± SEM of seven experiments. At the right, a representative image of the Western Blot is 
presented. 
 
Postsynaptic density protein 95 (PSD-95) is a membrane associated guanylate kinase scaffolding 
protein located in postsynaptic densities (Stathakis et al., 1997). The levels of PSD-95 were 
quantified by Western Blotting to evaluate postsynaptic density and no significant changes were 
found between the levels of this protein in Tg(CaMKII-hA2AR) (n=6) when comparing to WT 
littermates (n=6) (P>0.05) (Figure 4.5). 
 
 
Figure 4.5 - PSD-95 levels in the rat hippocampus. Immunoreactivity of PSD-95 was measured in whole tissue 
homogenates either for WT (black) or Tg(CaMKII-hA2AR) (white) animals. Specific immunoreactivity was normalized to that 
of GAPDH. Results are the mean ± SEM of six experiments. At the right, a representative image of the Western Blot is 
presented. 
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4.3 | Effects of A2AR overexpression in glial cell reactivity 
Since noxious brain conditions and neurodegenerative processes are characterized by alterations 
in glial cell function, reactivity profile of microglia and astrocytes were evaluated in CaMKII-hA2AR 
transgenic model, in order to assess if neuronal-specific overexpression of A2AR drives changes in 
glial reactivity. 
 
4.3.1 | Characterization of Microglial Phenotype 
 
4.3.1.1 | Analysis of Iba1 immunoreactivity 
Microglial reactivity was evaluated by Western Blotting through the levels of Iba1, a protein with a 
suggested role in calcium homeostasis that is known to be upregulated following microglial activation 
(Ito et al., 2001). Analysis of Iba1 reactivity (Figure 4.6) revealed an increase of 66.91 ± 24.77% 
(P<0.05) in the levels of this microglial activation marker in Tg(CaMKII-hA2AR) rats (n=7) when 
comparing to WT littermates (n=7). 
 
Figure 4.6 -  Iba1 levels in the rat hippocampus. Immunoreactivity of Iba1 was measured in whole tissue homogenates 
either for WT (black) or Tg(CaMKII-hA2AR) (white) animals. Specific immunoreactivity was normalized to that of GAPDH. 
Results are the mean ± SEM of seven experiments. At the right, a representative image of the Western Blot is presented. 
(*): P<0.05 calculated using an unpaired Student’s t-test. 
 
 
4.3.1.2 | Morphological analysis of microglial cells 
Following the increase in microglial reactivity in Tg(CaMKII-hA2AR) animals assessed by Western 
Blotting (Figure 4.6), morphology of microglial cells was analysed in order to quantify differences in 
activation state (Figure 4.7).  
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Figure 4.7 - Morphological analysis of microglial cells. A minimum of 60 representative Iba+ cells of CA1 area were 
randomly selected per animal (a). After drawing cell perimeter (b), tracing was fitted into an ellipse (c), allowing the 
quantification of the area of influence and shape of individual cells by measuring its parameters. 
 
Microglial activation process is characterized by high morphological plasticity, consisting in a 
multistage morphological transformation from a ramified to amoeboid appearance, through the 
reduction of cell shape complexity and acquisition of characteristics resembling peripheral 
macrophages (Kettenmann et al., 2011). Therefore, the angle and area of the fitted ellipse were 
evaluated as a mean to infer about the shape of microglial cells. 
 
Analysis of the area of the fitted ellipse revealed a significant decrease of 4,64x108 ± 5,134x107 
µm2 (P<0.05) in the area occupied by individual microglial cells of CA1 region in Tg(CaMKII-hA2AR) 
rats (n=3) when comparing to WT littermates (n=2) (Figure 4.8). 
 
Figure 4.8 - Area occupied by individual microglial cells of CA1 area of hippocampus. A minimum of 60 
representative Iba+ cells of CA1 area were randomly selected per each WT (black) (n=2) and Tg(CaMKII-hA2AR) (white) 
(n=3) animals. Analysis was performed through the area of the ellipse fitted to each individual cell tracing. Results are 
presented as the mean ± SEM. At the right, representative images of the microglial phenotype are presented. Scale Bar: 
25µm. (*): P<0.05 calculated using an unpaired Student’s t-test. 
Iba1 
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In what concerns the analysis of the angle of the fitted ellipse, results revealed that microglial cells 
of CA1 area of Tg(CaMKII-hA2AR) animals (n=3) have a less rounded shape when comparing to WT 
littermates (n=2), as indicated by a significant increase in ellipse elongation (16400 ± 6908) (P<0.05) 
(Figure 4.9). 
 
Figure 4.9 – Elongation of individual microglial cells of CA1 area of hippocampus. A minimum of 60 representative 
Iba+ cells of CA1 area were randomly selected per each WT (black) (n=2) and Tg(CaMKII-hA2AR) (white) (n=3) animals. 
Analysis was performed through the angle of the ellipse fitted to each individual cell tracing. Results are presented as the 
mean ± SEM. At the right, representative images of the microglial phenotype are presented. Scale Bar: 25µm. (*): P<0.05 
calculated using an unpaired Student’s t-test. 
 
 
4.3.1.3 | Microglial cell counts and CD11b expression levels 
Increased expression of a binding protein for intracellular cell adhesion molecule-1 and 
complement C3bi (CD11b) has been correlated with the severity of microglial activation in several 
neuroinflammatory diseases (Roy et al., 2006). Therefore, hippocampal microglial cells in CaMKII-
hA2AR transgenic model were characterized by flow cytometry using CD11b as surface marker, 
quantifying both microglial population and its overall expression of CD11b. 
The first approach consisted of a Percoll gradient, with the aim of establishing correct gatings for 
microglial cells using a purified sample. The population of interest was identified based on 
parameters of size/viability (FSC), granularity (SSC) and relative expression of CD11b (FL1) and 
CD45 (FL2) (CD45lowCD11b+) (Figure 4.10). 
  
Iba1 
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Figure 4.10 – Gating of microglial population for Flow Cytometry analysis. A Percoll gradient was performed with 
hippocampal tissue from WT and Tg(CaMKII-hA2AR) animals (n=2). Cells were gated based on parameters of size/viability 
(FSC), granularity (SSC) and relative expression of CD11b (FL1) and CD45 (FL2) (CD45lowCD11b+). 
CD45 intensity in gated cells was lower than predicted, when assuming microglial phenotype as 
CD45lowCD11b+ (Figure 4.10). In order to ensure correct isolation of the population of interest, CD45 
antibody staining was tested using lymph node samples and proven not to be effective 
(Supplementary Figure 7.6). Consequently, the presence of macrophages and monocytes 
(CD45highCD11b+) in our isolated cell population could not be entirely excluded. However, since 
microglia are considered to be the only cells that express CD11b in intact brain, due to the absence 
of leukocytes infiltrating brain tissue (Jeong et al., 2013), we assumed CD11b+ cells as our population 
of interest. 
Therefore, in order to perform a quantitative analysis of total microglial cell number in the 
hippocampus, previous gating was applied in non-purified samples and the total number of CD11b+ 
cells per 650000 total scanning events was analysed. No significant differences were found in total 
CD11b+ cell number between Tg(CaMKII-hA2AR) (n=2) and WT littermates (n=2) (P>0.05) (Figure 
4.11). 
         WT                      Tg(CaMKII-hA2AR) 
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Figure 4.11 – CD11b+ cell number in the hippocampus. Non-purified hippocampal samples from WT and Tg(CaMKII-
hA2AR) animals (n=2). Cells were gated based on parameters of size/viability (FSC), granularity (SSC) and relative 
expression of CD11b (FL1) and CD45 (FL2) (CD45lowCD11b+). Results are presented as the mean ± SEM, per 650000 
total scanning events.   
         WT       Tg(CaMKII-hA2AR) 
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In what concerns the overall expression of CD11b fluorescence, no significant differences were 
found in CD11b Median Fluorescence Intensity between Tg(CaMKII-hA2AR) (n=2) and WT 
littermates (n=2) (P>0.05) (Figure 4.12). 
 
 
 
 
Figure 4.12 – CD11b Fluorescence Intensity. Non-purified hippocampal samples from WT and Tg(CaMKII-hA2AR) 
animals (n=2). Cells were gated based on parameters of size/viability (FSC), granularity (SSC) and relative expression of 
CD11b (FL1) and CD45 (FL2) (CD45lowCD11b+). At the left, histogram of CD11b Fluorescence Intensity in WT and 
Tg(CaMKII-hA2AR) samples (n=2). At the right, results are presented as the mean ± SEM of the CD11b Median 
Fluorescence Intensity (n=2). 
 
4.3.2 | Characterization of Astroglial Phenotype 
 
4.3.2.1 | Analysis of GFAP immunoreactivity 
Astrocytic reactivity was assessed using the levels of GFAP, a member of the intermediate filament 
family of proteins suggested to be involved in the control of shape, movement and function of 
astroglial cells (Eng et al., 2000) that is overexpressed following their activation. Immunoblot analysis 
revealed a significant decrease of 20.76 ± 8.019% (P<0.05) in GFAP protein levels of Tg(CaMKII-
hA2AR) rats (n=7) when comparing to WT littermates (n=7) (Figure 4.13). 
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Figure 4.13 - GFAP levels in the rat hippocampus. Immunoreactivity of GFAP was measured in whole tissue 
homogenates either for WT (black) or Tg(CaMKII-hA2AR) (white) animals. Specific immunoreactivity was normalized to that 
of GAPDH. Results are the mean ± SEM of seven experiments. At the right, a representative image of the Western Blot is 
presented. (*): P<0.05 calculated using an unpaired Student’s t-test. 
 
4.3.2.2 | Morphological Analysis of Astroglial Cells 
Overall morphology of hippocampal astrocytes was evaluated by GFAP immunohistochemistry, 
in order to investigate if A2AR overexpression in forebrain neurons had influence on the density, 
distribution and phenotype of astroglial cells. 
No apparent changes were found in overall astroglial phenotype by GFAP 
immunohistochemistry (Figure 4.14). 
Figure 4.14 - Overall astroglial phenotype in hippocampus. Fluorescence immunohistochemistry composition of 
hippocampus of WT and Tg(CaMKII-hA2AR) animals at 10x magnification. At the top, representative images of astroglial 
phenotype at CA1 area of hippocampus are presented. Scale Bar: 25µm. Neuronal nuclei are stained with Hoechst (blue) 
and astrocytes are identified by red fluorescence using mouse anti-GFAP antibody (Millipore).  
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A detailed assessment of astrocytic morphology was then performed by Sholl Analysis of 
GFAP+ cells of CA1 area, stained by DAB immunohistochemistry. No significant changes were 
detected in length and complexity of astroglial processes, between Tg(CaMKII-hA2AR) (n=3) and WT 
littermates (n=2) (P>0.05) (Figure 4.15). 
 
Figure 4.15 - Length and complexity of astroglial processes in CA1 area. Morphology of 90 GFAP+ cells from each WT 
(black) (n=2) and Tg(CaMKII-hA2AR) (white) (n=3) animals was evaluated by Sholl Analysis. Results are the mean of 
process intersections per each concentric ring distributed at equal distances from cell body. Left panel: representative 
images of the method. Scale Bar: 40µm. 
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5 | DISCUSSION 
 
This study aimed to evaluate the impact on astrocytes and microglia of the pathological 
phenomena associated with A2A receptors dysregulation in the hippocampus. 
Our main findings show that A2AR overexpression conditional to the glutamatergic forebrain 
neurons - that mimics the long-term robust upregulation induced by noxious brain conditions - is 
sufficient to induce microglial activation and reduction of astroglial reactivity, resembling features of 
aging process. This corroborates the view of a modulatory potential of adenosine in the functional 
control of different cell subsets 
 
5.1 | Localization of human A2AR overexpression in the rat hippocampus 
It was confirmed that Tg(CaMKII-hA2AR) animals overexpress the human A2AR in CA3 axonal 
projections and in the neuropil of DG and CA1 hippocampal areas. Further analysis with Electron 
Microscopy using neuronal markers would be useful, in order to evaluate the localization of A2AR 
overexpression with a higher resolving power. 
The homology between human A2AR and rat A2AR is about 84-85%, with receptors being 
functionally similar, activated by endogenous adenosine and coupled to a Gs protein (Giménez-Llort 
et al., 2007). Functional significance of human A2AR overexpressed in the rat is demonstrated by the 
results of the synaptic transmission characterization performed by our group. 
Tg(CaMKII-hA2AR) model allowed the confirmation of the hypothesis that A2AR upregulation in 
neurons is sufficient to drive synaptic dysfunction and cognitive impairment in a mechanism that 
mimics hippocampal aging (Temido-Ferreira et al., 2015). 
 
5.2 | Neuronal A2AR overexpression induced alterations in microglia  
Overall, results of microglial cell characterization pointed towards a difference in microglial 
phenotype between Tg(CaMKII-hA2AR) animals and WT littermates that may reflect alterations in 
activation profile (Figure 5.1). 
Microglial phenotype of Tg(CaMKII-hA2AR) animals consisted of cells with higher elongation, 
decreased area of influence, shorter ramifications, and increased Iba1 immunoreactivity, suggesting 
that neuronal-specific overexpression of A2AR induces a primed state of microglia, triggering 
morphological alterations that resemble early stages of activation process. 
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Figure 5.1 – Representative images and schematic representation of differences in microglial phenotype. 
Representative fluorescence images of microglial cells from CA1 area of WT and Tg(CaMKII-hA2AR) hippocampal sections 
at 63x magnification. Microglia are identified by red fluorescence using goat anti-Iba1 antibody (Abcam). At the top, a 
schematic representation of Microglial activation sequence (adapted from 
http://bioweb.biology.uiowa.edu/daileylab/projects.html)  
 
Since precise detection of different stages of activation process through morphologic analysis is 
one of the major challenges in microglial research (Das Sarma et al., 2013), combined histological 
and flow cytometry analysis are crucial to perform a full phenotypic characterization, taking the 
differential expression of surface markers into account. 
Although increased CD11b expression is known to be associated with microglial activation (Roy et 
al., 2006), in current study Iba1 upregulation is not correlated with an increase in CD11b expression 
levels. However, as characterization was performed under basal conditions, such activated 
phenotype is not expected to occur in a physiological context, with substantial pathology being 
required to take microglia into a higher state of activation, in order to increase CD11b expression. 
Moreover, several studies have considered Iba1 a better marker for morphological differentiation 
(Das Sarma et al., 2013), since it has major roles in calcium signalling, RacGTPase activation and 
membrane ruffling, important features in macrophage activation (Kanazawa et al., 2002). 
  
Iba1 
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Chronic microglial activation is an important component of neurodegenerative diseases, 
contributing to CNS dysfunction and injury (González-Scarano & Baltuch, 1999). Aging process - 
strongest risk factor for neurodegeneration - is characterized by a significant increase in microglial 
activation, together with an upregulation of genes related to cellular stress and inflammation, as well 
as a decrease of growth factors and trophic support (reviewed in Lucin & Wyss-Coray, 2009). 
Accordingly, microglia derived from aged mice show process retraction and increased basal 
production of proinflammatory mediators, namely TNFα, IL-1β and IL-6, reflecting a hypersensitive 
preconditioned state, that causes a more rapid and pronounced response upon any insult, creating 
an inflammatory microenvironment which promotes degeneration (Olah et al., 2011). 
The molecular pathways underlying microglial-induced neuroinflammation gain relevance since 
several studies have described a potential role of microglia in plasticity and function of synaptic 
circuits in the mature CNS, associating soluble factors released by microglia and actions upon basal 
transmission and synaptic plasticity (reviewed in Schafer et al., 2013). Electrophysiology studies with 
microglial-conditionated medium have demonstrated a potentiation of NMDA receptor-mediated 
postsynaptic responses (Moriguchi et al., 2003) and enhancement of LTP (Hayashi et al., 2006) as 
well as modulation of basal glutamatergic transmission (Pascual et al., 2012), reinforcing the 
functional significance of microglial activation and paracrine signalling on synaptic activity, having 
IL-1β (Nisticò et al., 2013; Simões et al., 2012), glycine, L-serine (Hayashi et al., 2006) and ATP 
(Pascual et al., 2012) as principal molecular mediators. 
Therefore, current results corroborate the hypothesis of A2AR dysregulation as an early-aging 
mechanism in the hippocampus, with a microglial primed phenotype that may contribute for the 
alterations of synaptic transmission observed in Tg(CaMKII-hA2AR) animals (Temido-Ferreira et al., 
2015), mimicking features of aging process. It suggests that once neuronal-specific A2AR 
overexpression triggers a primed/preconditionated microglial state, it may favour the secretion of 
proinflammatory factors that can damage neurons and alter synaptic transmission, promoting the 
establishment of a chronic microenvironmental alteration. This, in turn, would lead to the subsequent 
activation of microglia, enhancing neuroinflammatory status and leading to a self-perpetuating cycle 
that would, ultimately, lead to neurodegeneration. 
Moreover, different brain insults also cause an upregulation of the expression and density of A2AR 
in activated microglia (Canas et al., 2004; Yu et al., 2008). In vitro and in vivo studies clearly 
demonstrate that A2AR controls several important functions operated by microglia, mediating process 
retraction (Gyoneva et al., 2014; Orr et al., 2009), synthesis and release of inflammatory mediators, 
levels of inflammatory enzymes and proliferation (Santiago et al., 2014). As such, although A2AR 
effects have been attributed to actions in neuronal receptors, blockade of microglial A2AR might also 
yield neuroprotection through direct actions in this cellular subset. Furthermore, the vicious loop 
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caused by a chronic shift of microenvironment towards inflammation in Tg(CaMKII-hA2AR) animals 
might concomitantly result from the activation of microglial A2AR. 
All gathered, results point towards the therapeutic interest of identifying regulatory systems capable 
of rebalancing microglial function in the management of the progression of neurodegenerative 
diseases. 
 
5.3 | Neuronal A2AR overexpression induced alterations in astrocytes 
Results of astroglial cell characterization indicate that neuronal-specific A2AR overexpression 
induces alterations in astrocytic reactivity by decreasing GFAP immunoreactivity, without influencing 
the density, distribution and morphology of astroglial cells. 
Factors reducing astrocyte activation, as measured by the expression levels of GFAP, have not 
been sufficiently studied (Pekny et al., 2016). Early stages of neurodegenerative diseases are 
characterized by an asthenic phenotype of astroglial cells, with substantial loss of function 
(Verkhratsky et al., 2015). 
Among many homeostatic functions, astrocytes have an important role in supporting synaptic 
transmission, namely by regulating ion concentrations in the synaptic cleft, providing energetic 
metabolites to neurons, performing the uptake of neurotransmitters and supplying neuronal terminals 
with glutamine, an obligatory precursor for glutamate and GABA (Pekny et al., 2016). Therefore, 
astroglial loss of function is directly connected to the reduction of homeostatic support, having 
detrimental effects on the multipartite synapse. 
Particularly, the accumulation of extracellular glutamate and consequent excitotoxicity phenomena 
contribute directly to the establishment and progression of most neurodegenerative diseases, 
highlighting the impact of glutamate transporters in the control of synaptic plasticity (Benarroch, 
2010). Interestingly, GFAP expression was found to be required for the accurate expression and 
trafficking of astrocytic (EAAT1) and neuronal (EAAT2) glutamate transporters, with the loss of this 
intermediate filament protein resulting in an overall decrease in glutamate transport (Hughes et al., 
2004). LTP/LTD probability is highly dependent on synaptic glutamate concentrations, thus, an 
impairment in the uptake of this neurotransmitter resulting from an asthenic astrocytic phenotype 
could contribute to the alterations in synaptic transmission observed in Tg(CaMKII-hA2AR) animals 
(Temido-Ferreira et al., 2015). 
Moreover, astroglial asthenia has been described in various forms of neuropathology, from 
psychiatric to neurodegenerative diseases. Studies on mood disorders correlate specific deficits in 
GFAP expression in corticolimbic circuits with depressive-like behaviour in animal models (Gosselin 
et al., 2009) and Major Depression Disorder in humans (Si et al., 2004). Little is yet known on the 
aetiology of this correlation, remaining the speculation on whether the astroglial defect is the cause 
 47 
 
or a direct consequence of anxiety and stress. Nonetheless, it has also been demonstrated that 
paradigms of chronic stress (Imbe et al., 2012; Tynan et al., 2013) and chronic unpredictable mild 
stress (Ye et al., 2011) also selectively decreased GFAP expression, without reducing astrocytic 
numbers and specific pharmacological ablation of astrocytes induces a depressive-like behaviour 
similar to that observed following chronic stress (Banasr & Duman, 2007). 
In aging, experimental data is still controversial, and aging effects on astroglial physiology remain 
generally unknown, with both increase in astroglial reactivity and astrocytic senescence being 
reported in aged animals (reviewed in Rodríguez-Arellano et al., 2015). 
Since Tg(CaMKII-hA2AR) animals display altered exploratory behaviour, anhedonic-like phenotype 
and increased behavioural despair - key features of depressive-like behaviour (Coelho et al., 2014) 
that are in line with the depressive signs found in aging, chronic stress and AD, a link is suggested 
between forebrain A2AR overexpression and a functional disruption of astroglial cells. 
On the other hand, although the actions of A2AR have mainly been assumed to result from the 
activation of neuronal A2AR, this type of receptor is also present in astrocytes, mediating glucose 
metabolism, astrogliosis, proliferation, cellular volume and the release of neurotrophic factors and 
interleukins (reviewed in Boison et al., 2010 and Daré et al., 2007).  
Orr et al. (2015) concluded that astrocytic A2AR regulate memory and may mediate aberrant effects 
under pathological conditions, by modulating processes underlying memory storage or 
consolidation, such as synaptic plasticity and neural network activity. Coincidentally, it is also known 
that the activation of astrocytic A2AR decreases the uptake of glutamate by inhibiting the activity and 
expression of EEAT1 and EAAT2 (Matos et al., 2012). Therefore, our results suggest that the 
features of depressive-like behaviour (Coelho et al., 2014), memory impairments and synaptic 
alterations (Temido-Ferreira et al., 2015) that characterize Tg(CaMKII-hA2AR) model might be 
partially seen as a consequence of the loss of astroglial function driven by neuronal-specific A2AR 
overexpression and may also involve activation of astroglial A2AR.  
Furthermore, by suggesting that astrocytes influence the pathophysiology of A2AR dysregulation, 
the results highlight the therapeutic interest of modulating astrocytic function in pathological 
conditions. 
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6 | CONCLUSIONS 
 
In conclusion, our results prove the ability of neuronal-specific A2AR overexpression to impact on 
glial cell function. A2AR dysregulation underlying synaptic dysfunction and cognitive impairments in 
Tg(CaMKII-hA2AR) model derives from a synergy of synaptic and glial dysfunction, resembling 
features of hippocampal aging (summarized in Figure 6.1). 
The present results contribute to acknowledge neurocentrism as an obsolete theory in the study of 
neurological diseases, highlighting the importance of considering neurodegeneration as a 
consequence of homeostatic failure, giving relevance to the molecular and cellular changes in glia 
as well as neurons, when trying to decipher the mechanisms leading to neuropathology. 
Also the current study suggests A2AR as a promising pharmacological target in neurodegenerative 
diseases, allowing a multifactorial approach with the aim of slowing down their progression. 
 
 
Figure 6.1 – Schematic representation of functional interrelations between neuronal, microglial and astrocyctic 
phenotypes in Tg(CaMKII-hA2AR) model. Broken arrows indicate connections that are not fully characterized. Relevant 
references: Benarroch, 2010, Neurology; Hughes et al., 2004, Brain Res Mol Brain Res; Matos et al., 2012, Glia; Orr et al., 
2015, Nat Neurosci.; Orr et al., 2009, Nat Neurosci.; Pekny et al., 2016, Acta Neuropathol.; Santiago et al., 2014, Mediators 
Inflamm.; Schafer et al., 2013, Glia; Temido-Ferreira et al., 2015; Verkhratsky et al., 2015, Neuroscientist. 
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7 | SUPPLEMENTARY DATA 
 
 
Supplementary Figure 7.1 – DNA construct used to generate Tg(CaMKII-hA2AR) rats. Construct consists of a full-
length human A2A cDNA cloned into an expression vector with the 8.5kb mouse CaMKIIα promoter and a polyadenylation 
cassete of bovine growth hormone. (Michael Bader, MDC, Berlin). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7.2 – Sequence of the 450bp PCR product specific for Tg(CaMKII-hA2AR). FLAG-tag is in 
frame with hA2AR and inserted between the 6th and 7th aminoacids of the N-terminal of transgenic human A2AR protein. 
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Supplementary Figure 7.3 - FLAG staining by immunohistochemistry. Fluorescence immunohistochemistry images 
from CA1 area of 12µm rat hippocampal sections at 63x magnification. Neuronal nuclei are stained with Hoechst (blue) 
and FLAG is identified by green fluorescence using rabbit anti-FLAG antibody (Sigma-Aldrich). Scale Bar: 25µm. 
 
 
 
 
 
Supplementary Figure 7.4 - Rabbit anti-FLAG antibody (Sigma-Aldrich) staining profile by Western Blotting 
Analysis. Staining profile and specificity were evaluated by Western Blotting analysis, using a protein sample containing 
a FLAG-tag as a positive control (2µg) (1), and whole tissue hippocampal homogenates from a Wistar rat (WT) (2) and a 
Tg(CaMKII-hA2AR) animal (3) (20µg). 
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Supplementary Figure 7.5 – Molecular Features of CaMKII-hA2AR overexpression. Tg(CaMKII-hA2AR) animals show 
an A2AR overexpression in the forebrain, evaluated by in situ hybridization (1) and confirmed by qPCR (2). A2AR protein 
levels increase from 2 weeks-old onwards in the hippocampus (3), in the pre-synaptic region (4), without affecting A1R 
levels (5). Results were analysed using unpaired Student’s t-test for each gene/brain area, (*) P<0.05 compared to WT. 
(Lopes et al, unpublished) 
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Supplementary Figure 7.6 – Flow Cytometry Analysis of CD45 antibody staining profile in rat lymph node sample. 
Unstained sample (1); sample stained with PE-conjugated anti-CD45 (OX30) antibody (Santa Cruz Biotechnologies) and 
FITC-conjugated anti-integrin αM/CD11b (OX42) antibody (Santa Cruz Biotechnologies) at 1:200 concentration (2). Cells 
were gated based on parameters of size/viability (FSC), granularity (SSC). 
 
 
 
  
 55 
 
8 | ACKNOWLEDGEMENTS 
 
No final desta etapa de grande crescimento profissional e pessoal, não posso deixar de agradecer 
a todos os que - directa ou indirectamente - contribuíram para que esta dissertação fosse possível: 
Às minhas orientadoras, pela simpatia, amizade e toda a ajuda e motivação ao longo desta 
jornada, sobretudo quando a frustração teimava em ser palavra de ordem. Um imenso obrigada por 
me darem o privilégio de dar os primeiros passos em investigação científica sabendo que não 
poderia ter escolhido melhor. 
À Luísa, pelo voto de confiança ao receber-me no seu grupo, por todos os ensinamentos e valiosos 
momentos de discussão científica, por ser para mim um exemplo na ciência e fora dela.  
À Joana, pela paciência, cumplicidade, preocupação e carinho demonstrados diariamente, que 
não me deixaram esmorecer perante os vários desafios com que nos fomos deparando. Obrigada 
por todos os conhecimentos, ideias e brainstormings e por me teres sempre dado espaço para 
pensar e evoluir. 
Aos colegas de laboratório que me receberam de braços abertos e me fazem sentir de coração 
cheio por pertencer a um grupo definido pelo verdadeiro espírito de equipa. 
Ao Rui, por tudo o que me ensinou, por ser incansável e estar sempre disponível para juntar ciência 
e uma boa dose de gargalhadas. 
À Mariana, Diana, Miguel e Vânia, por toda a disponibilidade e ajuda, aliadas a uma imensa 
cumplicidade, que fizeram com que o laboratório fosse muito mais do que um local de trabalho. 
Obrigada por trocarem o desespero por sorrisos e serem, mais do que colegas, amigos. 
Às várias pessoas que me comprovaram que a simpatia, entreajuda e partilha de conhecimentos 
são o motor do sucesso. 
Ao Biotério de Roedores (IMM) pelo apoio na manutenção da colónia. 
À Unidade de Bioimagem (IMM), particularmente ao José Rino, Ana Nascimento e António 
Temudo, por toda a disponibilidade e ajuda com a aquisição e análise de imagens. 
À Julie Ribot e Pedro Papotto (Bruno Silva-Santos Lab) e Ana Vieira (Unidade de Citometria de 
Fluxo, IMM), pela preciosa ajuda com o mundo da citometria de fluxo. 
À Tânia Carvalho (Laboratório de Histologia e Patologia Comparada, IMM) e ao Pedro Pereira 
(Serviço de Neuropatologia, Hospital Santa Maria) pela ajuda relacionada com a histologia. 
Ao André Bastos (CEDOC, UNL) pela ajuda no processo de preparação de neurónios dissociados. 
À Mariana, por estares comigo desde o primeiro momento desta tão importante etapa, pelo carinho 
e forte amizade e por acreditares mais em mim do que eu própria. 
Ao Jorge, por estares incondicionalmente ao meu lado, partilhando comigo todas as alegrias e 
frustrações, e por apesar das ausências, faltas e maus humores fazeres sempre um esforço para 
beber do entusiasmo que sinto pela ciência. 
56 
 
Ao Winga, por me ensinares que a música é a sincronia que se gera sem serem necessárias 
palavras. Obrigada pela paciência e cumplicidade, por todas as vezes em que conseguiste aligeirar 
o peso de um dia menos bom e ajudar-me a encontrar motivação para continuar a manter o ritmo. 
À minha família, pelo apoio incondicional e por me proporcionarem a possibilidade de seguir aquilo 
que me fascina. 
À minha mãe, meu eterno porto de abrigo, todas as palavras serão poucas. Obrigada por nunca 
me deixares desistir, inspirando-me desde sempre a fazer mais e melhor. 
 
  
 57 
 
9 | REFERENCES 
Almolda, B., de Labra, C., Barrera, I., Gruart, A., Delgado-Garcia, J. M., Villacampa, N., … Castellano, B. 
(2015). Alterations in microglial phenotype and hippocampal neuronal function in transgenic mice with 
astrocyte-targeted production of interleukin-10. Brain, Behavior, and Immunity, 45, 80–97. 
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., … Potter, H. (2009). Caffeine 
reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease 
mice. Journal of Alzheimer’s Disease: JAD, 17, 661–680. 
Banasr, M., & Duman, R. S. (2007). Regulation of neurogenesis and gliogenesis by stress and antidepressant 
treatment. CNS & Neurological Disorders Drug Targets, 6, 311–320. 
Batalha, V. L., Pego, J. M., Fontinha, B. M., Costenla, A. R., Valadas, J. S., Baqi, Y., … Lopes, L. V. (2013). 
Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores 
corticosterone circadian oscillation. Molecular Psychiatry, 18, 320–331. 
Benarroch, E. E. (2010). Glutamate transporters: diversity, function, and involvement in neurologic disease. 
Neurology, 74, 259–264. 
Biber, K., Neumann, H., Inoue, K., & Boddeke, H. W. G. M. (2007). Neuronal “On” and “Off” signals control 
microglia. Trends in Neurosciences, 30, 596–602. 
Boison, D., Chen, J.-F., & Fredholm, B. B. (2010). Adenosine signaling and function in glial cells. Cell Death 
and Differentiation, 17, 1071–1082. 
Canas, P., Rebola, N., & Rodrigues, R. (2004). Increased adenosine A2A immunoreactivity in activated rat 
microglia in culture (Vol. A223.9). Presented at the 4th Forum of European Neuroscience. 
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., … Ransohoff, R. M. 
(2006). Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience, 9, 917–
924. 
Coelho, J. E., Alves, P., Canas, P. M., Valadas, J. S., Shmidt, T., Batalha, V. L., … Lopes, L. V. (2014). 
Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and 
Anxiety. Frontiers in Psychiatry, 5, 67. 
Cristóvão-Ferreira, S., Vaz, S. H., Ribeiro, J. A., & Sebastião, A. M. (2009). Adenosine A2A receptors enhance 
GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. Journal of 
Neurochemistry, 109, 336–347. 
Cunha, R. A. (2005). Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor 
blockade. Purinergic Signalling, 1, 111–134. 
58 
 
Cunha, R. A., & Ribeiro, J. A. (2000). Adenosine A2A receptor facilitation of synaptic transmission in the CA1 
area of the rat hippocampus requires protein kinase C but not protein kinase A activation. 
Neuroscience Letters, 289, 127–130. 
Dai, S. S., Zhou, Y. G., Li, W., An, J. H., Li, P., Yang, N., … Chen, J. F. (2010). Local Glutamate Level Dictates 
Adenosine A2A Receptor Regulation of Neuroinflammation and Traumatic Brain Injury. Journal of 
Neuroscience, 30, 5802–5810. 
Daré, E., Schulte, G., Karovic, O., Hammarberg, C., & Fredholm, B. B. (2007). Modulation of glial cell functions 
by adenosine receptors. Physiology & Behavior, 92, 15–20. 
Das Sarma, S., Chatterjee, K., Dinda, H., Chatterjee, D., & Das Sarma, J. (2013). Cytomorphological and 
Cytochemical Identification of Microglia. ISRN Immunology, 2013, 1–10. 
Diógenes, M. J., Costenla, A. R., Lopes, L. V., Jerónimo-Santos, A., Sousa, V. C., Fontinha, B. M., … 
Sebastião, A. M. (2011). Enhancement of LTP in Aged Rats is Dependent on Endogenous BDNF. 
Neuropsychopharmacology, 36, 1823–1836. 
Doorn, K. J., BrevÃ©, J. J. P., Drukarch, B., Boddeke, H. W., Huitinga, I., Lucassen, P. J., & van Dam, A.-M. 
(2015). Brain region-specific gene expression profiles in freshly isolated rat microglia. Frontiers in 
Cellular Neuroscience, 9. doi:10.3389/fncel.2015.00084 
Eng, L. F., Ghirnikar, R. S., & Lee, Y. L. (2000). Glial fibrillary acidic protein: GFAP-thirty-one years (1969-
2000). Neurochemical Research, 25, 1439–1451. 
Ferreira, D. G., Batalha, V. L., Vicente Miranda, H., Coelho, J. E., Gomes, R., Gonçalves, F. Q., … Lopes, L. 
V. (2015). Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity. Cerebral Cortex 
(New York, N.Y.: 1991). doi:10.1093/cercor/bhv268 
Ford, A. L., Goodsall, A. L., Hickey, W. F., & Sedgwick, J. D. (1995). Normal adult ramified microglia separated 
from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences 
defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells 
compared. Journal of Immunology (Baltimore, Md.: 1950), 154, 4309–4321. 
Fredholm, B. B., Chen, J.-F., Cunha, R. A., Svenningsson, P., & Vaugeois, J.-M. (2005). Adenosine and brain 
function. International Review of Neurobiology, 63, 191–270. 
Fredholm, B. B., Chern, Y., Franco, R., & Sitkovsky, M. (2007). Aspects of the general biology of adenosine 
A2A signaling. Progress in Neurobiology, 83, 263–276. 
Gao, Z., & Tsirka, S. E. (2011). Animal Models of MS Reveal Multiple Roles of Microglia in Disease 
Pathogenesis. Neurology Research International, 2011, 383087. 
 59 
 
Giménez-Llort, L., Schiffmann, S. N., Shmidt, T., Canela, L., Camón, L., Wassholm, M., … Bader, M. (2007). 
Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the 
brain. Neurobiology of Learning and Memory, 87, 42–56. 
González-Scarano, F., & Baltuch, G. (1999). Microglia as mediators of inflammatory and degenerative 
diseases. Annual Review of Neuroscience, 22, 219–240. 
Gosselin, R.-D., Gibney, S., O’Malley, D., Dinan, T. G., & Cryan, J. F. (2009). Region specific decrease in glial 
fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience, 159, 
915–925. 
Gyoneva, S., Shapiro, L., Lazo, C., Garnier-Amblard, E., Smith, Y., Miller, G. W., & Traynelis, S. F. (2014). 
Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process 
extension in a model of Parkinson’s disease. Neurobiology of Disease, 67, 191–202. 
Hayashi, Y., Ishibashi, H., Hashimoto, K., & Nakanishi, H. (2006). Potentiation of the NMDA receptor-mediated 
responses through the activation of the glycine site by microglia secreting soluble factors. Glia, 53, 
660–668. 
Hodel, A. (1998). SNAP-25. The International Journal of Biochemistry & Cell Biology, 30, 1069–1073. 
Hooper, C., & Pocock, J. (2015, October 27). An overview of microglia subtypes and markers. Retrieved from 
http://www.abcam.com/neuroscience/an-overview-of-microglia-subtypes-and-markers 
Hughes, E. G., Maguire, J. L., McMinn, M. T., Scholz, R. E., & Sutherland, M. L. (2004). Loss of glial fibrillary 
acidic protein results in decreased glutamate transport and inhibition of PKA-induced EAAT2 cell 
surface trafficking. Molecular Brain Research, 124, 114–123. 
Hu, X., Li, P., Guo, Y., Wang, H., Leak, R. K., Chen, S., … Chen, J. (2012). Microglia/Macrophage Polarization 
Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia. Stroke, 43, 
3063–3070. 
Imbe, H., Kimura, A., Donishi, T., & Kaneoke, Y. (2012). Chronic restraint stress decreases glial fibrillary acidic 
protein and glutamate transporter in the periaqueductal gray matter. Neuroscience, 223, 209–218. 
Ito, D., Tanaka, K., Suzuki, S., Dembo, T., & Fukuuchi, Y. (2001). Enhanced expression of Iba1, ionized 
calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke; a 
Journal of Cerebral Circulation, 32, 1208–1215. 
Jeong, H.-K., Ji, K., Min, K., & Joe, E.-H. (2013). Brain Inflammation and Microglia: Facts and Misconceptions. 
Experimental Neurobiology, 22, 59. 
60 
 
Ji, K., Miyauchi, J., & Tsirka, S. E. (2013). Microglia: an active player in the regulation of synaptic activity. 
Neural Plasticity, 2013, 627325. 
Kanazawa, H., Ohsawa, K., Sasaki, Y., Kohsaka, S., & Imai, Y. (2002). Macrophage/microglia-specific protein 
Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma -dependent 
pathway. The Journal of Biological Chemistry, 277, 20026–20032. 
Kay, A. R., & Wong, R. K. (1986). Isolation of neurons suitable for patch-clamping from adult mammalian 
central nervous systems. Journal of Neuroscience Methods, 16, 227–238. 
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011). Physiology of Microglia. Physiological 
Reviews, 91, 461–553. 
Kettenmann, H., & Verkhratsky, A. (2011). Neuroglia, der lebende Nervenkitt. Fortschritte der Neurologie · 
Psychiatrie, 79, 588–597. 
Khoa, N. D., Postow, M., Danielsson, J., & Cronstein, B. N. (2006). Tumor necrosis factor-alpha prevents 
desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma 
membrane. Molecular Pharmacology, 69, 1311–1319. 
Kumar, A., Stoica, B. A., Sabirzhanov, B., Burns, M. P., Faden, A. I., & Loane, D. J. (2013). Traumatic brain 
injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and 
alternative activation states. Neurobiology of Aging, 34, 1397–1411. 
Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., … Blum, D. (2016). A2A adenosine 
receptor deletion is protective in a mouse model of Tauopathy. Molecular Psychiatry, 21, 97–107. 
Lawson, L. J., Perry, V. H., & Gordon, S. (1992). Turnover of resident microglia in the normal adult mouse 
brain. Neuroscience, 48, 405–415. 
Lee, F. S., & Chao, M. V. (2001). Activation of Trk neurotrophin receptors in the absence of neurotrophins. 
Proceedings of the National Academy of Sciences of the United States of America, 98, 3555–3560. 
Liao, B., Zhao, W., Beers, D. R., Henkel, J. S., & Appel, S. H. (2012). Transformation from a neuroprotective 
to a neurotoxic microglial phenotype in a mouse model of ALS. Experimental Neurology, 237, 147–
152. 
Lopes, L. V., Cunha, R. A., Kull, B., Fredholm, B. B., & Ribeiro, J. A. (2002). Adenosine A(2A) receptor 
facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. 
Neuroscience, 112, 319–329. 
 61 
 
Lopes, L. V., Cunha, R. A., & Ribeiro, J. A. (1999). Increase in the number, G protein coupling, and efficiency 
of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. Journal of 
Neurochemistry, 73, 1733–1738. 
Lucin, K. M., & Wyss-Coray, T. (2009). Immune Activation in Brain Aging and Neurodegeneration: Too Much 
or Too Little? Neuron, 64, 110–122. 
Magistretti, P., & Ransom, B. (2002). Astrocytes. In K. David, D. Charney, J. Coyle, & C. Nemeroff (Eds.), 
Neuropsychopharmacology: The Fifth Generation of Progress (pp. 133–145). American College of 
Neuropsychopharmacology. 
Malek, R. L., Nie, Z., Ramkumar, V., & Lee, N. H. (1999). Adenosine A(2A) receptor mRNA regulation by nerve 
growth factor is TrkA-, Src-, and Ras-dependent via extracellular regulated kinase and stress-activated 
protein kinase/c-Jun NH(2)-terminal kinase. The Journal of Biological Chemistry, 274, 35499–35504. 
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012). Mechanisms underlying the rapid peroxisome 
proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a 
murine model of Alzheimer’s disease. The Journal of Neuroscience: The Official Journal of the Society 
for Neuroscience, 32, 10117–10128. 
Maragakis, N. J., & Rothstein, J. D. (2006). Mechanisms of Disease: astrocytes in neurodegenerative disease. 
Nature Clinical Practice Neurology, 2, 679–689. 
Marcoli, M., Raiteri, L., Bonfanti, A., Monopoli, A., Ongini, E., Raiteri, M., & Maura, G. (2003). Sensitivity to 
selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia 
in rat cerebrocortical slices. Neuropharmacology, 45, 201–210. 
Matos, M., Augusto, E., Santos-Rodrigues, A. D., Schwarzschild, M. A., Chen, J.-F., Cunha, R. A., & Agostinho, 
P. (2012). Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. 
Glia, 60, 702–716. 
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR 
in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology, 38, 1285–1291. 
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987). Reactive microglia in patients with senile 
dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. 
Neuroscience Letters, 79, 195–200. 
Mikita, J., Dubourdieu-Cassagno, N., Deloire, M. S., Vekris, A., Biran, M., Raffard, G., … Petry, K. G. (2011). 
Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple 
62 
 
sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Multiple Sclerosis 
(Houndmills, Basingstoke, England), 17, 2–15. 
Morel, G. R., Andersen, T., Pardo, J., Zuccolilli, G. O., Cambiaggi, V. L., Hereñú, C. B., & Goya, R. G. (2015). 
Cognitive impairment and morphological changes in the dorsal hippocampus of very old female rats. 
Neuroscience, 303, 189–199. 
Moriguchi, S., Mizoguchi, Y., Tomimatsu, Y., Hayashi, Y., Kadowaki, T., Kagamiishi, Y., … Nakanishi, H. 
(2003). Potentiation of NMDA receptor-mediated synaptic responses by microglia. Brain Research. 
Molecular Brain Research, 119, 160–169. 
Nisticò, R., Mango, D., Mandolesi, G., Piccinin, S., Berretta, N., Pignatelli, M., … Centonze, D. (2013). 
Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis. PLoS 
ONE, 8, e54666. 
Oberheim, N. A., Goldman, S. A., & Nedergaard, M. (2012). Heterogeneity of Astrocytic Form and Function. 
In R. Milner (Ed.), Astrocytes (Vol. 814, pp. 23–45). Totowa, NJ: Humana Press. 
Olah, M., Biber, K., Vinet, J., & W.G.M. Boddeke, H. (2011). Microglia Phenotype Diversity. CNS & 
Neurological Disorders - Drug Targets, 10, 108–118. 
Orr, A. G., Hsiao, E. C., Wang, M. M., Ho, K., Kim, D. H., Wang, X., … Mucke, L. (2015). Astrocytic adenosine 
receptor A2A and Gs-coupled signaling regulate memory. Nature Neuroscience, 18, 423–434. 
Orr, A. G., Orr, A. L., Li, X.-J., Gross, R. E., & Traynelis, S. F. (2009). Adenosine A2A receptor mediates 
microglial process retraction. Nature Neuroscience, 12, 872–878. 
Pascual, O., Ben Achour, S., Rostaing, P., Triller, A., & Bessis, A. (2012). Microglia activation triggers 
astrocyte-mediated modulation of excitatory neurotransmission. Proceedings of the National Academy 
of Sciences of the United States of America, 109, E197–205. 
Pedersen, W. A., Wan, R., Zhang, P., & Mattson, M. P. (2002). Urocortin, but not urocortin II, protects cultured 
hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone 
receptor type I. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22, 
404–412. 
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J.-M., Parpura, V., … Verkhratsky, A. (2016). 
Astrocytes: a central element in neurological diseases. Acta Neuropathologica, 131, 323–345. 
Pocock, J. M., & Kettenmann, H. (2007). Neurotransmitter receptors on microglia. Trends in Neurosciences, 
30, 527–535. 
 63 
 
Rebola, N., Oliveira, C. R., & Cunha, R. A. (2002). Transducing system operated by adenosine A(2A) receptors 
to facilitate acetylcholine release in the rat hippocampus. European Journal of Pharmacology, 454, 
31–38. 
Rebola, N., Simões, A. P., Canas, P. M., Tomé, A. R., Andrade, G. M., Barry, C. E., … Cunha, R. A. (2011). 
Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal 
dysfunction: A2A receptors control neuroinflammation. Journal of Neurochemistry, 117, 100–111. 
Ribeiro, J. A., & Sebastião, A. M. (2010). Modulation and metamodulation of synapses by adenosine: 
Adenosine modulation and metamodulation. Acta Physiologica, 199, 161–169. 
Ribeiro, J. A., Sebastiao, A. M., & de Mendonca, A. (2003). Participation of adenosine receptors in 
neuroprotection. Drug News & Perspectives, 16, 80–86. 
Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., & Verkhratsky, A. (2015). Astrocytes in physiological aging 
and Alzheimer’s disease. Neuroscience. doi:10.1016/j.neuroscience.2015.01.007 
Rosenzweig, E. S., & Barnes, C. A. (2003). Impact of aging on hippocampal function: plasticity, network 
dynamics, and cognition. Progress in Neurobiology, 69, 143–179. 
Roy, A., Fung, Y. K., Liu, X., & Pahan, K. (2006). Up-regulation of Microglial CD11b Expression by Nitric Oxide. 
Journal of Biological Chemistry, 281, 14971–14980. 
Santiago, A. R., Baptista, F. I., Santos, P. F., Cristóvão, G., Ambrósio, A. F., Cunha, R. A., & Gomes, C. A. 
(2014). Role of Microglia Adenosine A 2A Receptors in Retinal and Brain Neurodegenerative Diseases. 
Mediators of Inflammation, 2014, 1–13. 
Schafer, D. P., Lehrman, E. K., & Stevens, B. (2013). The “quad-partite” synapse: Microglia-synapse 
interactions in the developing and mature CNS. Glia, 61, 24–36. 
Schulte, G., & Fredholm, B. B. (2003). Signalling from adenosine receptors to mitogen-activated protein 
kinases. Cellular Signalling, 15, 813–827. 
Sebastiao, A., & Ribeiro, J. (2009). Tuning and Fine-Tuning of Synapses with Adenosine. Current 
Neuropharmacology, 7, 180–194. 
Sedgwick, J. D., Schwender, S., Imrich, H., Dörries, R., Butcher, G. W., & ter Meulen, V. (1991). Isolation and 
direct characterization of resident microglial cells from the normal and inflamed central nervous 
system. Proceedings of the National Academy of Sciences of the United States of America, 88, 7438–
7442. 
64 
 
Shechter, R., & Schwartz, M. (2013). Harnessing monocyte-derived macrophages to control central nervous 
system pathologies: no longer “if” but “how”: Macrophages beyond inflammation in CNS pathologies. 
The Journal of Pathology, 229, 332–346. 
Simões, A., Duarte, J. A., Agasse, F., Canas, P., Tomé, A. R., Agostinho, P., & Cunha, R. A. (2012). Blockade 
of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through 
a p38 mitogen-activated protein kinase pathway. Journal of Neuroinflammation, 9, 204. 
Si, X., Miguel-Hidalgo, J. J., O’Dwyer, G., Stockmeier, C. A., & Rajkowska, G. (2004). Age-Dependent 
Reductions in the Level of Glial Fibrillary Acidic Protein in the Prefrontal Cortex in Major Depression. 
Neuropsychopharmacology, 29, 2088–2096. 
Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathologica, 119, 7–
35. 
Stathakis, D. G., Hoover, K. B., You, Z., & Bryant, P. J. (1997). Human postsynaptic density-95 (PSD-95): 
location of the gene (DLG4) and possible function in nonneural as well as in neural tissues. Genomics, 
44, 71–82. 
Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverría, C., Orellana, J. A., … Retamal, M. A. 
(2012). Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear 
memory consolidation in the basolateral amygdala. FASEB Journal: Official Publication of the 
Federation of American Societies for Experimental Biology, 26, 3649–3657. 
Stellwagen, D., & Malenka, R. C. (2006). Synaptic scaling mediated by glial TNF-alpha. Nature, 440, 1054–
1059. 
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008). Synuclein activates 
microglia in a model of Parkinson’s disease. Neurobiology of Aging, 29, 1690–1701. 
Tambuyzer, B. R., Ponsaerts, P., & Nouwen, E. J. (2009). Microglia: gatekeepers of central nervous system 
immunology. Journal of Leukocyte Biology, 85, 352–370. 
Tebano, M. T., Martire, A., Pepponi, R., Domenici, M. R., & Popoli, P. (2006). Is the functional interaction 
between adenosine A(2A) receptors and metabotropic glutamate 5 receptors a general mechanism in 
the brain? Differences and similarities between the striatum and the hippocampus. Purinergic 
Signalling, 2, 619–625. 
Temido-Ferreira, M., Coelho, J. E., Ferreira, D. G., Outeiro, T. F., Bader, M., Marie, H., … Lopes, L. V. (2015). 
Neuronal Adenosine A2A Receptor Overexpression affects AMPA and NMDA currents in CA1 
 65 
 
hippocampal neurons. Presented at the 45th Annual Meeting of the Society for Neurocience, Chicago, 
U.S.A. 
Towbin, H., Staehelin, T., & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of 
Sciences of the United States of America, 76, 4350–4354. 
Tynan, R. J., Beynon, S. B., Hinwood, M., Johnson, S. J., Nilsson, M., Woods, J. J., & Walker, F. R. (2013). 
Chronic stress-induced disruption of the astrocyte network is driven by structural atrophy and not loss 
of astrocytes. Acta Neuropathologica, 126, 75–91. 
Verkhratsky, A., Marutle, A., Rodriguez-Arellano, J. J., & Nordberg, A. (2015). Glial Asthenia and Functional 
Paralysis: A New Perspective on Neurodegeneration and Alzheimer’s Disease. The Neuroscientist, 
21, 552–568. 
Wu, M., Nissen, J. C., Chen, E. I., & Tsirka, S. E. (2012). Tuftsin promotes an anti-inflammatory switch and 
attenuates symptoms in experimental autoimmune encephalomyelitis. PloS One, 7, e34933. 
Ye, Y., Wang, G., Wang, H., & Wang, X. (2011). Brain-derived neurotrophic factor (BDNF) infusion restored 
astrocytic plasticity in the hippocampus of a rat model of depression. Neuroscience Letters, 503, 15–
19. 
Yu, L., Shen, H.-Y., Coelho, J. E., Araújo, I. M., Huang, Q.-Y., Day, Y.-J., … Chen, J.-F. (2008). Adenosine A 
2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. 
Annals of Neurology, 63, 338–346. 
 
